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ABSTRACT 
 The generation of amyloid-β (Aβ) peptides through proteolytic processing of the 
amyloid precursor protein (APP) is a key pathogenic event in Alzheimer’s disease (AD). 
Aβ generation begins with APP endocytosis, which is mediated by the endocytic 
YENPTY sequence located in the cytoplasmic tail of APP. Mints, a family of cytosolic 
adaptor proteins, directly bind to the YENPTY motif of APP and facilitate APP 
endocytosis and amyloidogenic processing. In addition, loss of any one of the three Mint 
proteins decreases Aβ production in aging mouse models of AD, supporting the 
hypothesis that the APP-Mint interaction may provide a novel therapeutic target to 
selectively reduce Aβ production in AD.  
Characterizing the biochemical and cellular dynamics of the APP-Mint interaction 
is critical for understanding Aβ generation. Thus, we generated Mint1 mutants that bind 
with high affinity (Mint1Y633A) or low affinity (Mint1Y549A/F610A) to APP. These Mint1 
mutants exhibited profound alterations in cellular localization, APP endocytosis, and Ab 
production. Therapeutically, we generated a novel cell-permeable APP mimetic peptide 
(APPMP) that interferes with the APP-Mint interaction. This APPMP was designed to 
	
	 viii 
outcompete endogenous APP binding, with a 46-fold improved affinity to Mint. 
Treatment of primary neurons from an AD mouse model with several cell permeable 
APPMP variants reduced Ab production with minimal cellular toxicity, supporting Mints 
as a promising novel therapeutic target for AD.  
The PTB domain of Mint1 that mediates APP binding is autoinhibited by an 
adjacent C-terminal α-helix. However, the molecular mechanisms underlying the relief of 
Mint1 autoinhibition are unclear. Since post-translational modification is one mechanism 
for alleviating protein autoinhibition, and Mint1 is highly regulated by phosphorylation, 
we performed mass spectrometry and identified several Mint1 phosphosites. In addition, 
we found constitutively-active Src kinase, a kinase implicated in Mint phosphorylation, 
enhanced APP-Mint1 binding. These results suggest that Src kinase-mediated 
phosphorylation of Mint1 may relieve Mint1 autoinhibition and promote APP-Mint1 
interaction. Overall, this work biochemically characterized the Mint-APP interaction and 
how it affects amyloidogenic processing, provided a proof of concept for targeting the 
APP-Mint1 interaction as an AD therapeutic target, and suggested a novel mechanism for 
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CHAPTER ONE: Introduction 
1.1 Alzheimer’s disease (AD) overview  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most 
common cause of dementia in the United States, accounting for between 60% and 80% of 
all dementia cases. An estimated 6.2 million Americans 65 and older are living with AD, 
and unless a disease modifying treatment becomes available, it is projected the 
prevalence could increase more than two-fold by 2050. AD-associated medical costs 
create an immense financial burden in the United States. In fact, costs associated with the 
health care and long-term care of AD patients are predicted to reach $1.1 trillion in 2050. 
AD is the sixth leading cause of death in the United States, and there is only one 
provisionally Food and Drug Administration (FDA)-approved treatment (introduced in 
June 2021) (Mullard, 2021). As this novel drug is only provisionally approved, it still has 
to pass a confirmatory trial.  Thus, there is still a critical need for novel AD treatments 
that can slow the progression, prevent, or cure the disease (Alzheimer’s Association, 
2021).    
AD is named after Dr. Alois Alzheimer, who first described the disease in 1907 as 
“an unusual illness of the cerebral cortex.” In the article, he described a 51-year-old 
woman who exhibited symptoms such as disorientation, memory loss, and delirium. 
Following the patient’s passing, Dr. Alzheimer conducted a post-mortem examination of 
her brain, identifying brain atrophy, intraneuronal tangles of fibrils, and an accumulation 




tangles of fibrils and extracellular foci in the cortex would eventually become the 
neuropathological hallmarks that define AD.  
The symptoms of AD accumulate over time, worsening as neurodegeneration spreads 
throughout the brain. As such, the clinical diagnoses of AD evolve over time, progressing 
from preclinical AD, to mild cognitive impairment (MCI), and finally to dementia due to 
AD. The pre-clinical stage of AD isn’t always associated with cognitive symptoms, but 
some patients can experience subtle declines in episodic memory, the ability to learn and 
retain new information (Sperling et al., 2011). MCI is characterized by a decline in 
episodic memory, language, attention control, and executive functions such as reasoning, 
problem solving, and planning (Albert et al., 2011). A patient is diagnosed with dementia 
due to AD when their cognitive or behavioral symptoms represent a decline from 
previous levels of function, interfere with their ability to function at work or usual 
activities, and are not explained by delirium or a major psychiatric disorder. At this stage, 
cognitive and behavioral impairments can occur in the following domains: acquiring and 
remembering new information; reasoning and handling of complex tasks; visuospatial 
abilities; language functions; and personality, behavior, or demeanor. Common 
symptoms include asking repetitive questions, misplacing personal belongings, the 
inability to recognize faces or common objects, difficulty thinking of common words 
while speaking, and uncharacteristic mood fluctuations, such as agitation, impaired 
motivation, and social withdrawal (McKhann et al., 2011).  
AD is typically categorized into two groups depending on the age of onset of the 




and late-onset AD (LOAD), with symptoms appearing after 65 years of age (Rossor et 
al., 2010). The majority of cases are classified as LOAD, while only about 5% of AD 
cases are categorized as EOAD (Zhu et al., 2015). EOAD is further subcategorized into 
early-onset familial Alzheimer’s disease (EOFAD), which comprises only 10% of EOAD 
cases (~0.5% of all AD cases) (Wingo et al., 2012). These EOFAD cases are caused by 
autosomal dominant mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), 
or presenilin 2 (PSEN2), which are genes related to the production of amyloid-beta (Ab), 
the main pathological component found in the extracellular foci seen in AD (discussed 
later in this chapter). The remaining EOAD cases are attributed to summed polygenic 
susceptibility (reviewed in (Mendez, 2019).  
1.2 Neuropathological hallmarks of AD  
The defining neuropathological features of AD are intraneuronal neurofibrillary 
tangles (NFTs) and extracellular Aβ plaques (Mattson, 2004). NFTs are insoluble 
aggregates of hyperphosphorylated tau, a microtubule associated protein abundant in 
axons. The normal function of tau is to stabilize microtubules. However, in pathological 
conditions, tau becomes hyperphosphorylated, triggering conformational changes that 
cause it to disassociate from microtubules. As the cytosolic concentration of tau 
increases, it becomes more likely to misfold, increasing its propensity to aggregate. 
Misfolded tau first aggregates into pretangles, which then form b-sheet-containing paired 
helical filaments (PHFs) that further aggregate into insoluble NFTs (reviewed in 
(Ballatore et al., 2007). In most AD clinicopathological studies, NFTs correlate better 




exhibit a characteristic distribution pattern, which facilitates the classification of six 
individual stages (Braak stages) that are used for the neuropathological staging of AD 
(Braak and Braak, 1991).  
Extracellular Aβ plaques are insoluble accumulations of Aβ peptides that arise 
from sequential proteolytic cleavage of the amyloid precursor protein (APP) by b- and g-
secretases (reviewed by (Nunan and Small, 2000). Aβ is a 38-42 amino acid hydrophobic 
peptide that first aggregates into soluble oligomers and then aggregates into insoluble 
fibrils, commonly called senile plaques. Previous studies have demonstrated that 
aggregation of Aβ into higher order oligomers (e.g., dimers, trimers etc.) is essential for 
toxicity in neurons (Haass and Selkoe, 2007; Walsh and Selkoe, 2007). The Aβ42 
peptide, which oligomerizes quicker than other common forms of Aβ, is consequently 
considered the most toxic species (Hilbich et al., 1991).  
The precise mechanism by which Ab oligomers exert their toxicity is widely 
debated; however, a number of studies have interrogated possible mechanisms. Ab 
oligomers have been shown to bind to a number of neuronal cell surface receptors such as 
cellular prion protein, p75 neurotrophin receptor, β2-adrenergic receptor, and α7-
nicotinic acetylcholine receptor, altering their downstream signaling and causing 
neurotoxicity (reviewed in (Huang and Liu, 2020). Other work has shown that Ab 
oligomers trigger the internalization and degradation of α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPAR), an excitatory postsynaptic receptor critical 
for synaptic plasticity (Zhang et al., 2018). Ab oligomers also over-activate N-Methyl-D-




excess calcium influx into neurons promoting excitotoxicity (Alberdi et al., 2010). Ab 
can also directly insert into the plasma membrane of neurons, disrupting membrane 
integrity via inducing reactive oxygen species and lipid peroxidation, which perturbs 
membrane fluidity and ion permeability (Yasumoto et al., 2019). In fact, Ab oligomers 
can create ion permeable pores via directly inserting into the plasma membrane, further 
perturbing intracellular calcium levels (Arispe et al., 1993). The dysregulation of calcium 
homeostasis in neurons changes the activity of neuronal phosphatases (such as 
calcineurin) and kinases (such as GSK3b); this aberrant phosphorylation activity leads to 
the hyperphosphorylation of tau (Reese and Taglialatela, 2011). The disruption in 
calcium homeostasis can also cause mitochondrial dysfunction, triggering apoptosis 
(Supnet and Bezprozvanny, 2010). In fact, calcium dysregulation has been implicated by 
numerous lines of evidence to facilitate Ab toxicity and subsequent neurodegeneration 
(Cascella and Cecchi, 2021).  
1.3 Evidence to support the Aβ hypothesis  
As AD is defined by two pathologic hallmarks, NFTs and Aβ plaques, the 
pathogenic relationship between these structures as well as their contribution to the 
disease state has been heavily investigated and intensely debated. Three decades ago, 
several major investigators in the AD field postulated the amyloid cascade hypothesis, 
which proposed that Aβ accumulation is the primary influence driving AD pathogenesis 
(Beyreuther and Masters, 1991; Hardy and Allsop, 1991; Hardy and Higgins, 1992; 
Selkoe, 1991). According to the Ab hypothesis, the sequence of major pathogenic events 




of Ab42, causing subtle toxic effects on synaptic transmission, (3) gradual deposition of 
Ab42 oligomers into diffuse plaques, (4) microglial and astrocytic activation, causing 
inflammatory responses, (5) oxidative stress and altered neuronal ionic homeostasis, (6) 
altered kinase and phosphatase activity, leading to tau hyperphosphorylation and 
aggregation into NFTs, (7) synaptic dysfunction and neuronal loss, and (8) dementia 
[Figure 1.1] (reviewed in (Selkoe and Hardy, 2016). In short, the Ab hypothesis 
postulates that Ab accumulation is an early, initiating step in AD.   
 Several lines of evidence support the Aβ hypothesis, including both experimental 
and human genetics data. Experimentally, exposing normal rat neurons in vitro to soluble 
Ab oligomers isolated from human AD cortex is sufficient to induce AD-type tau 
hyperphosphorylation, microtubule cytoskeletal disruptions, and neuron degeneration, all 
pathogenic signatures of AD. When the same Ab is added to neurons lacking endogenous 
tau, the downstream neuron degeneration doesn’t occur, further supporting that Ab 
initiates the cascade that causes tau aggregation, which then leads to neuron dystrophy 
(Jin et al., 2011). In addition, injecting healthy adult rodent brain with soluble Ab isolated 
from human AD brains is sufficient to impair synaptic plasticity and memory, inducing 
an AD phenotype (Shankar et al., 2008). From a human AD context, stem-cell derived 
neurons differentiated from skin cells of EOFAD individuals exhibit Ab accumulation 
initially, with tau aggregation appearing later, supporting Ab is an early driver of AD 
pathology. In these differentiated human neurons, decreasing Ab production using 




phenotypes, further supporting that Ab drives tau pathology (Choi et al., 2014; Moore et 
al., 2015; Muratore et al., 2014; Shi et al., 2012).  
Genetically, there is strong evidence to support the Ab hypothesis. First, all 
dominant mutations in humans that cause EOFAD occur in either the substrate (APP) or 
the protease (presenilin) from the reaction that generates Ab (Cacace et al., 2016). 
Second, there is a co-morbidity of AD and Down’s syndrome because those individuals 
have three copies of chromosome 21, which carries the APP gene (Potter et al., 2016). In 
fact, there was a rare individual with partial trisomy 21 that lacked the extra APP gene; 
the patient exhibited Down’s features but did not develop AD, further supporting the 
specific contribution of APP overexpression to AD (Prasher et al., 1998). Third, 
mutations in tau cause frontotemporal dementia with parkinsonism, but lack the 
characteristic Aβ plaques associated with AD (Poorkaj et al., 1998).  
In an effort to establish the etiology of AD, a number of studies have identified 
various genetic risk loci associated with AD. The e4 apolipoprotein E (APOE) allele, 
originally identified as a major risk factor for AD (Corder et al., 1993), has since been 
confirmed via genome-wide association studies (GWAS) to be the strongest genetic risk 
locus for LOAD. Human APOE has three polymorphic alleles (e2, e3, and e4); 
individuals carrying the e4 allele have an increased risk of AD compared to individuals 
carrying the common e3 allele, whereas the e2 allele confers a decrease in AD risk. ApoE 
plays a role in Ab clearance, and studies in both human and transgenic mice revealed that 
brain Ab levels and plaque loads are ApoE isoform dependent, with e4>e3>e2 (reviewed 




number of novel susceptibility gene variants associated with LOAD (reviewed in 
(Andrews et al., 2020). The susceptibility genes identified in these large-scale GWAS 
studies are implicated in three major cellular processes: lipid metabolism (e.g ABCA7), 
inflammatory response (e.g complement receptor 1 (CR1), CD33, and TREM2) and 
endocytosis (SORL1 and PICALM) (Karch and Goate, 2015). Interestingly, both APOE4 
and most of the novel genes identified in the recent GWAS studies affect Ab production 
and clearance, which supports the Ab hypothesis. With considerable evidence supporting 
the amyloid hypothesis, comprehensive studies of APP trafficking and processing are 
fundamental for the mechanistic understanding of AD as well as the future development 
of therapeutic strategies. 
1.4 Current amyloid-targeted AD therapeutic strategies  
Developing a disease-modifying preventative treatment for AD has been on the 
forefront of pharmaceutical research for many years. Until recently, there were only two 
classes of FDA approved drugs for the symptomatic treatment of AD: (1) acetylcholine 
esterase inhibitors, aimed at increasing the availability of the neurotransmitter 
acetylcholine, which is depleted in AD patients; and (2) a NMDAR antagonist, which 
prevents overstimulation of neurons. However, these treatments only ameliorate dementia 
symptoms (reviewed in (Huang and Mucke, 2012).  
A number of therapies have been influenced by the Ab hypothesis, specifically 
targeting the production or accumulation of Ab in the brain. A comprehensive analysis of 
the AD clinical trial pipeline from January 2021 revealed that of the 17 “disease 




accumulation, while only 1 agent (6%) targeted the aggregation of tau (Cummings et al., 
2021). For a list of amyloid-targeting agents in Phase 3 clinical trials as of January 2021 
[Table 1.1].  
However, a number of Ab targeted approaches that reached Phase 3 clinical trials 
have failed (Karran et al., 2011). In fact, two Phase 3 clinical trials of aducanumab, 
Biogen’s human monoclonal antibody designed to clear Ab fibrils and oligomers, were 
terminated following a futility analysis. However, Biogen’s post-hoc analysis revealed 
that participants receiving their high dose aducanumab had a 22% slower rate of 
cognitive decline compared to those receiving placebo after 78 weeks (Fillit and Green, 
2021). Thus, Biogen submitted an application to the FDA for a biologics license for 
aducanumab (now marketed as Aduhelm) to be utilized as an AD treatment, and it was 
recently provisionally approved under the accelerated review pathway (Mullard, 2021).  
The failure of numerous Ab-targeting drugs may raise apprehension about the Ab 
hypothesis, but it is important to consider which stage in the disease progression these 
therapeutic interventions were administered. As with the majority of AD clinical trials, 
the Aducanumab patient cohort exhibited MCI due to AD, meaning the pathogenic Ab 
cascade had already been initiated. It is still unclear at which stage of the disease an 
Ab directed therapeutic would need to be administered to have the greatest chance of 
clinical efficacy. A study conducted by the Alzheimer’s Prevention Initiative is designed 
to interrogate if early, preventative treatment before the onset of clinical symptoms would 
be efficacious. The study is detailing the effectiveness of crenezumab, a monoclonal 




carrying the EOFAD mutation (PSEN1 E280A) (Tariot et al., 2018). This study will 
provide critical insight into whether pre-clinical AD treatment could lead to better 
outcomes. Another important consideration when designing an efficacious disease 
modifying agent is how much Ab production needs to be lowered, or Ab clearance 
facilitated, to reach the critical threshold of disease-modifying therapeutic effectiveness? 
This threshold is unknown, which means that although therapeutics are capable of 
clearing some Ab accumulation, it is possible that the critical tipping point has not been 
reached (Karran et al., 2011). Although most Ab targeting agents have struggled to 
survive past Phase 3 clinical trials, the recent provisional approval of Aduhelm provides 
support that targeting Ab is a viable AD treatment strategy.  
1.5 Amyloid precursor protein (APP) 
In 1984, Drs. Glenner and Wong isolated and purified toxic Ab fragments from 
human AD brains. Their analysis revealed that Ab is a 4.2 kDa fragment derived from the 
cleavage of a larger precursor protein (Glenner and Wong, 1984). Years later, this 
hypothesis was verified when another lab cloned the parent precursor protein, later 
named amyloid precursor protein (APP) (Kang et al., 1987). The APP family of proteins 
also includes apl-1 in Caenorhabditis elegans, APP-like (appl) in Drosophila, and APP 
like protein 1 (APLP1) and APP like protein 2 (APLP2) in mammals. However, the Ab 
peptide domain is unique to APP and not conserved across all family members (reviewed 
in (Zheng and Koo, 2006).  
APP is a ubiquitous type I transmembrane glycoprotein with a large extracellular 




has three major splice variants: APP695, APP751, and APP770 (Dawkins and Small, 
2014). APP695 is predominantly expressed in the central nervous system, while APP751 
and APP770, are expressed ubiquitously throughout all tissues (Sisodia et al., 1993). A 
number of functional subdomains exist in the extracellular region of APP, including the 
N-terminal growth factor-like domain (GFLD), metal binding motif (copper and zinc), 
heparin binding domains, and the Kunitz-type protease inhibitor (KPI) domain (that is 
only found in APP751 and 770 isoforms). The transmembrane region of APP spans the 
plasma membrane and also contains a portion of the Ab peptide. The cytoplasmic tail of 
APP contains a conserved endocytic YENPTY motif, which facilitates clathrin-mediated 
endocytosis of the protein (reviewed in (Reinhard et al., 2005).  
The physiological function of the APP family of proteins is not completely resolved, 
but a number of in vivo studies have implicated the family in processes related to 
neuronal and synaptic function. In Caenorhabditis elegans, RNAi-mediated knockdown 
of apl-1 caused defects in acetylcholine neurotransmission (Wiese et al., 2010). In 
Drosophila, appl knockout and knockdown studies revealed that during development, 
appl plays a role synaptic bouton formation and neurite outgrowth and then later in adult 
flies it contributes to synaptic plasticity and long-term memory (reviewed in (Poeck et al., 
2012). In mammals, single knockout studies cause subtle defects because APP, APLP1, 
and APLP2 have redundant functions (Zheng and Koo, 2006). Homozygous APP 
deficient mice exhibit decreased locomotor activity and reactive gliosis, suggesting 
neuronal damage (Zheng et al., 1995). Further studies revealed APP knockout mice 




marker density (Dawson et al., 1999). The importance of the mammalian APP family is 
underscored by the fact that knockout of all three APP family members (APP, APLP1, 
and APLP2) in mice causes cortical dysplasia, suggesting neuronal migratory defects, 
and is in fact lethal shortly following birth (Herms et al., 2004). To circumvent this 
perinatal lethality, mice with conditional APP/APLP1/APLP2 knockout in the excitatory 
neurons of the cerebral cortex were generated. These APP/APLP1/APLP2 conditional 
knockout mice exhibited hippocampal neuronal hyperexcitability as well as impairments 
in hippocampal synaptic plasticity, learning, and memory (Lee et al., 2020). Although the 
APP family of proteins is implicated in a number of processes, the aforementioned 
experimental evidence corroborates that the APP family of proteins exhibit conserved 
synaptic and neuronal functions.  
1.5.1 Neuronal APP trafficking and localization  
APP is synthesized and traffics through the secretory pathway, passing through 
the endoplasmic reticulum (ER) and accumulating in the trans-Golgi network. During its 
travel through the secretory pathway, APP undergoes a number of post-translational 
modifications, including N- and O- linked glycosylation, phosphorylation, and tyrosine 
sulfations (Yuksel and Tacal, 2019). APP can then be transported to both the dendrite and 
axons of neurons. Axonal transport of APP is thought to be mediated by the direct 
interaction of APP and the motor protein kinesin-1; however, this direct interaction is 
widely debated (Kamal et al., 2000; Kins et al., 2006; Koo et al., 1990). The mechanism 
of dendritic APP trafficking is unclear, but it is postulated that axonal APP undergoes 




accumulate at the presynaptic membrane, particularly in the presynaptic active zone 
(Weingarten et al., 2017; Wilhelm et al., 2014). This synaptic APP localization coincides 
with experiments that have shown Ab is synaptically released in vivo (Lazarov et al., 
2002). Once at the plasma membrane, APP is rapidly turned over, internalized via 
clathrin mediated-endocytosis which is mediated by the conserved YENPTY (an 
expansion of the canonical NPXY) sorting motif located in the intracellular C-terminus of 
APP (Lai et al., 1995). Following internalization, APP is trafficked through endocytic and 
recycling organelles either to the trans-Golgi, lysosome, or recycled back to the cell 
surface (Haass et al., 2012). A number of intracellular adaptor proteins interact with the 
endocytic YENPTY motif of APP, altering its endocytosis. These APP-interacting 
adaptor proteins include Mints, Fe65, Dab1, Shc, JIP-1, Numb, and Grb2 (reviewed in 
(Russo et al., 2005).  
1.5.2 APP processing  
APP is subject to proteolytic cleavage by one of two pathways: non-amyloidogenic or 
amyloidogenic. These proteolytic processes are dependent on the APP localization, as 
non-amyloidogenic processing starts at the plasma membrane and amyloidogenic 
processing starts within acidic endosomes. Non-amyloidogenic processing begins when 
α-secretase cleaves APP within the Aβ region, releasing a soluble APPα (sAPPα) 
ectodomain and a C-terminal transmembrane fragment alpha (CTFα). Further cleavage of 
the CTFα by γ-secretase releases a soluble p3 peptide and an APP intracellular domain 
(AICD). Amyloidogenic processing of APP begins in endosomes with β-secretase 




fragment beta (CTFβ), which is then cleaved by γ-secretase to release a soluble AICD 
and the Aβ peptide [Figure 1.2] (reviewed in (Haass et al., 2012).  
Mutations in APP that lead to EOFAD cluster within and around the Ab region of 
APP. To date, there are over 50 mutations identified in APP linked to EOFAD (Cacace et 
al., 2016). Mutations in the N-terminus of the Ab fragment, such as the Swedish 
mutation, create a better substrate for b-secretase activity and cause an increase in total 
Ab production. Mutations just C-terminal to the Ab sequence (such as the Austrian, 
Iranian, French, German, London, and Florida mutations) increase production of the 
longer Ab42 fragments, which are more prone to aggregate. Mutations in the middle of 
Ab (such as the Arctic and Dutch mutations), alter the conformation of the Ab oligomers 
and enhance their aggregation propensity (reviewed in (Haass et al., 2012).  
 Although the disease-associated Ab peptide is the most heavily studied APP 
proteolytic fragment, the other cleavage products of APP have also been functionally 
investigated. sAPPa has been shown to modulate synaptic transmission via binding to the 
a7 nicotinic acetylcholine receptor. Recently, both sAPPa and b have been shown to 
bind to and modulate the activity of metabotrophic GABAB receptors (reviewed in (Haass 
and Willem, 2019). The short AICD of APP can translocate to the nucleus and cause 
transcriptional activation (Cao and Südhof, 2001).  The exact gene targets of the AICD 
remain controversial, but some genes implicated include the Ab degrading enzyme 




The canonical secretases involved in APP processing have been identified and well 
characterized. ADAM10, the a-secretase primarily responsible for non-amyloidogenic 
APP cleavage in neurons, is a member of the “a disintegrin and metalloproteinase” 
family. ADAM10 is a type 1 transmembrane protein that is synthesized in the ER as a 
zymogen. As ADAM10 is trafficked thorough the secretory pathway, its pro-domain is 
removed and the catalytically active ADAM10 localizes to the plasma membrane 
(reviewed in (Manzine et al., 2019). Beta site APP Cleaving Enzyme 1 (BACE1) is the b-
secretase necessary for amyloidogenic APP cleavage. BACE1 largely localizes to 
endosomal compartments, mediated by its dileucine internalization motif (Huse et al., 
2000).  g-secretase, a member of the intramembrane cleaving proteases (iCLiPs), is a 
multimeric complex that consists of four proteins: nicastrin (NCT), anterior pharynx 
defective 1 (APH1), presenilin enhancer 2 (PEN2), and presenilin (PS).  The presenilin 
proteins [presenilin 1 (PS1) or presenilin 2 (PS2)] serve as the catalytic core of the g-
secretase complex (De Strooper and Annaert, 2010).  
PSEN1 is the most frequently mutated EOFAD associated gene, with more than 200 
mutations, while PSEN2 has roughly 30 EOFAD associated mutations (Cacace et al., 
2016). The molecular consequences of the EOFAD-linked PSEN mutations are often 
debated, with some people proposing a gain-of-toxic function and others attributing the 
increase of Ab42 to Ab40 ratio to a loss of function of presenilin. Interestingly, g-
secretase complex cleaves the Ab peptide multiple times sequentially. As such, the longer 
the time presenilin interacts with APP, the shorter and less pathogenic the Ab fragment 




many PSEN1/PSEN2 EOFAD mutations exhibit a loss of function (reviewed in (Weggen 
and Beher, 2012). In fact, in vitro protein stability assays have shown that EOFAD PSEN 
mutations destabilize the g-secretase-APP complex, a potential mechanism for the loss of 
function associated with the EOFAD presenilin mutations (Szaruga et al., 2017).  
APP as well as the secretases are dynamically sorted through the plasma membrane 
and the membrane of intracellular organelles. Consequently, colocalization of APP and β-
secretase in the same cellular compartment is a key influence on APP processing and Aβ 
production. Mature β-secretase localizes primarily in endosomes, where the endosomal 
acidic environment maximizes its activity, but also weakly at the cell surface and the 
trans-Golgi network (Das et al., 2013; Huse et al., 2000). Fluorescence resonance energy 
transfer (FRET) was employed to specifically investigate where the majority of APP and 
β-secretase interaction occurs in H4 glioma cells, with results indicating interaction 
occurs primarily in endosomes (Kinoshita et al., 2003). Further experimentation in 
primary neuronal culture using a technique based on biomolecular fluorescence 
complementation demonstrated most steady state BACE1 and APP interaction occurs in 
recycling endosomes (Das et al., 2013).   
As b-secretase cleavage, the initial step in Ab generation, occurs in acidic 
endosomes, the endocytosis of APP into b-secretase containing endosomes is a critical 
step in Ab production. A number of studies have shown that if APP endocytosis is 
impaired, there is a concomitant decrease in APP internalization and Ab generation. In 
Chinese hamster ovary (CHO) cells, deletion of the cytoplasmic tail of APP resulted in 




CHO cells introduced specific point mutations within APP’s YENPTY sorting motif, 
with mutations in Y, N, and P causing a decrease in APP internalization and Ab 
production (Perez et al., 1999). In vivo, inhibiting clathrin-mediated endocytosis via 
dominant negative dynamin in an AD mouse model caused a significant reduction in Aβ 
accumulation in the brain (Cirrito et al., 2008). Another supporting study revealed that 
knock-in mice expressing a truncated APP mutant lacking the YENPTY endocytic motif 
exhibit a significant reduction in brain Aβ levels as well (Ring et al., 2007). Thus, 
investigating potential avenues that decrease APP internalization and subsequent 
amyloidogenic processing can provide useful insights for potential future AD therapies. 
1.6 Mint family of adaptor proteins 
 The Mint (Munc-18 interacting) family of adaptor proteins consists of three 
distinct isoforms: Mint 1, 2, and 3. Mints are a family of multi-domain adaptors that form 
functionally relevant protein complexes. Over the years, Mint adaptor proteins have been 
referred to as X11 a/b/g, X11/L1/L2 or by their gene symbol APBA 1/2/3 (APP binding 
family A) (reviewed in (Rogelj et al., 2006). In humans there are three MINT genes, with 
MINT1, 2, and 3 encoded on chromosome 9, 15, and 19, respectively (Blanco et al., 1998; 
Duclos et al., 1993) (Tanahashi and Tabira, 1999). The Mint family is highly 
evolutionarily conserved, with orthologues in yeast (Mso1p), Caenorhabditis elegans 
(lin-10) and Drosophila (dX11L). All three Mint isoforms have been identified in most 
mammals studied to date (e.g., mouse, rat, chimpanzee, and cow) (reviewed in (Rogelj et 
al., 2006). Mints 1 and 2 are neuronal specific while Mint 3 is ubiquitously expressed 




and inhibitory neurons, Mint1 is selectively enriched in inhibitory interneurons. During 
mouse development, Mint2 is expressed early (around embryonic day 10.5) while Mint1 
express a little later in development (embryonic day 14.5) (Ho et al., 2003).  
1.6.1 Structure of Mints 
As adaptor proteins, Mints have a number of structured protein-protein interaction 
(PPI) domains that facilitate interaction with other proteins. Each Mint protein contains 
an-isoform specific amino N-terminus and a conserved carboxyl C-terminus [Figure 1.3]. 
Mint1 uniquely interacts with the calcium/calmodulin-dependent serine protein kinase 
(CASK) with high affinity via an N-terminal CASK interacting domain (CID) (Butz et 
al., 1998; Wu et al., 2020). CASK belongs to the membrane-associated guanylate kinase 
(MAGUK) family of scaffolding proteins, and it also interacts with a number of other 
presynaptic proteins (reviewed in (LaConte and Mukherjee, 2013). In fact, Mint1, CASK, 
and another presynaptic protein, Veli, were shown to form a tripartite complex that can 
act as a nucleation site for the assembly of presynaptic vesicle release machinery and 
synaptic adhesion molecules (Butz et al., 1998). Both Mint1 and 2 (but not Mint3) bind 
Munc-18, a protein essential for presynaptic vesicle exocytosis, via their N-terminal 
Munc-18 interaction domain (MID) (Okamoto and Sudhof, 1997; Verhage et al., 2000).  
The C-terminus of Mints is highly conserved, with 82% conservation between 
Mint1, 2, and 3. All three Mint isoforms have a phosphotyrosine binding (PTB) domain 
in their C-terminus.  This PTB domain of Mint adaptor proteins binds directly to the 
YENPTY motif of APP in a phosphorylation-independent manner (Borg et al., 1996; 




discovered, a number of mutational and structural analyses have extensively studied the 
binding interface between the PTB domain of Mints and the YENPTY motif of APP, 
illustrating the specificity of the interaction. In fact, the crystal structure of both Mint1 
and Mint2 PTB domains associated with the C-terminus of APP have been resolved 
(PDB ID: 4DBB and 3SV1, respectively). These crystal structures revealed that the C-
terminal linker region (which we termed the “autoinhibitory helix”) adjacent to the PTB 
domain of Mints1 and 2 can block the APP binding site (Matos et al., 2012; Xie et al., 
2012) [Figure 1.4]. 
Two other protein-protein interactions were also observed with the PTB domain 
of Mints, but these interactions are far less characterized. Mint1 PTB was shown to 
interact with phosphatidylinositol 4, 5-biposphate (PIP2), which suggests a potential role 
for Mints in vesicle docking to the membrane during exocytosis (Okamoto and Sudhof, 
1997) (Martin, 2012). The Mint2 PTB domain was also shown to bind a transmembrane 
protein named Alcadein (Alzheimer-related cadherin-like protein), and this binding could 
occur simultaneously with APP (Araki et al., 2003).  
The C-terminus of Mints 1-3 have two contiguous postsynaptic density 95, discs-
large /Zona-occludens-1 (PDZ) domains. PDZ domains are one of the largest class of PPI 
domains in the human proteome, and they are typically found in multidomain scaffold 
proteins involved in the trafficking, recruiting, and assembling of signal-transduction 
complexes (reviewed in (Christensen et al., 2019). The PDZ domains of Mints bind to a 
number of interaction partners, such as the presynaptic cell-adhesion molecule neurexins, 




channels (VGCC), which are critical for calcium influx into the presynaptic terminal 
(Maximov et al., 1999); the kinesin motor protein KIF17, which is involved in the 
transport of NMDAR subtype 2B (NR2B) in neurons (Setou et al., 2000); and Presenilin-
1, the catalytic core of the g-secretase complex (Lau et al., 2000). The interaction of 
Mints with two essential proteins for the production of Ab (APP and Presenilin-1) 
supports their merit as a potential AD therapeutic target.  
1.6.2 Mints’ synaptic function  
 Mints interact with a number of proteins that facilitate neuronal synaptic 
transmission. Mint1 localizes to the presynaptic active zone of neurons in mice 
hippocampus, which supports its potential role in synaptic vesicle release (Okamoto et 
al., 2000). Indeed, deletional analysis of Mints in mice has revealed their essential roles 
in synaptic vesicle release. Mint1 knockout mice specifically show an impairment in 
GABAergic synaptic vesicle release, which coincides with Mint1’s selective enrichment 
in inhibitory interneurons (Ho et al., 2003). Mint1/2 double knockout as well as Mint 
1/2/3 knockout in mice is postnatal lethal in 80% of mice. The surviving mice exhibit 
lower weight, motor impairments, reduced spontaneous neurotransmitter release, lowered 
synaptic strength, and a decreased presynaptic release probability. Interestingly, Mint1/3 
knockouts and Mint2/3 knockout survive, suggesting Mint1 and 2 may share redundant 
functions (Ho et al., 2006).  Mint1 has also been shown to be involved in the targeting of 
VGCC to hippocampal presynaptic terminals (Maximov and Bezprozvanny, 2002). 
Postsynaptically, Mints have been implicated in the localization of NMDAR excitatory 




trafficking of the NR2B subunit of NMDARs in dendrites (Setou et al., 2000). To support 
this finding, Mint1 and 2 double knockout mice exhibited a decrease in the level of 
extrasynaptic NMDARs (Motodate et al., 2019).   
1.6.3 Mints’ function in APP processing and AD  
 The role of Mints in APP processing has been studied by a number of labs, with 
contradictory results. In mammalian cell lines, such as HEK293 cells or N2A cells, 
overexpression of Mints stabilized APP, decreasing amyloidogenic processing and 
reducing Ab40 and 42 secretion (Borg et al., 1998) (Saito et al., 2011). However, RNAi 
knockdown of Mints1 and 2 in H4 human neuroglia cells also caused a decrease in Ab40 
production (Xie et al., 2005). These studies in mammalian cell lines raise the question 
whether Mints suppress or facilitate amyloidogenic APP processing. To clarify the role of 
Mints in APP processing, our lab conditionally knocked out all three Mints in primary 
murine neurons. Triple Mint knockout in neurons selectively reduced activity-induced 
APP endocytosis, which concomitantly decreased Ab42 release (Chaufty et al., 2012; 
Sullivan et al., 2014) [Figure 1.5]. Recent collaborative work from our lab further probed 
the APP-Mint2 interaction, creating an APP binding-deficient Mint2 mutant as well as an 
APP mimetic peptide designed to interfere with APP-Mint2 binding. Introduction of 
either the APP binding-deficient mutant or the cell-permeable APP mimetic peptide into 
primary AD mouse neurons significantly reduced Ab42 production, further confirming 
that Mints typically play a facilitative role in Ab formation (Bartling et al., 2021). These 




mutants mentioned earlier in this chapter, supporting the mechanism by which Mints 
facilitate APP endocytosis into b-secretase containing endosomes, accelerating 
amyloidogenic APP processing (Koo and Squazzo, 1994; Ring et al., 2007). As Mint 
proteins also interact via their PDZ domains with PS1, our lab illustrated that Mints 
promote APP/PS1 colocalization in mouse neurons (Sullivan et al., 2014) [Figure 1.5]. 
Because PS1 is vital for the second cleavage event that releases Ab, Mint’s dual role in 
facilitating APP endocytosis and promoting the interaction of APP with one of the 
amyloidogenic secretases makes Mints an attractive therapeutic target for AD.  
A number of labs have investigated how in vivo Mint knockouts in mice alter Ab 
accumulation, with conflicting results. Mint2 knockout mice as well as double Mint1/2 
knockout mice exhibited increased Ab accumulation at 12 months on a wild type 
background  (Saito et al., 2008; Sano et al., 2006). Further studies of Mint2 knockout 
mice crossed with transgenic mice expressing human APPswe also exhibited increased 
Ab accumulation at 12 months (Kondo et al., 2010). These knockout studies suggest that 
Mints typically suppress Ab production in vivo. However, in vivo work from our lab 
suggests that Mints typically facilitate Ab production. In fact, knockout of any of the 
three Mint proteins decreased Aβ accumulation in aged APPswe/PSEN1DE9 AD 
transgenic mice (Ho et al., 2008) [Figure 1.5]. The conflicting results between in vivo 
studies from our lab and others could potentially be attributed to differences in mouse 
background strains. It is also possible that Mints temporally regulate Ab production, 
meaning Ab alterations due to Mint knockouts could be less apparent at later time points 




Studies using human AD brain samples have further illuminated the role of Mint 
proteins in AD. Western blots from human AD parietal and occipital cortex revealed that 
Mint1 and 2 proteins are upregulated in AD patients (Jacobs et al., 2006). A recent study 
assessing copy number variants (CNVs) in AD patients revealed a duplication of the 
region encoding the Mint2 gene (APBA2) (El Bitar et al., 2020). Further, Mint2 has been 
found associated with neuritic plaques in the hippocampus and temporal cortex of human 
AD patients (McLoughlin et al., 1999).  
 The Mint/APP interaction has important pathological consequences relating to 
AD, so the potential regulatory mechanisms controlling this PPI have been studied in 
detail. Early work using deletional mutants of Mints in HEK cells revealed that Mint 
mutants lacking the sequence C-terminal to the PTB domain exhibited stronger APP 
binding but less Ab secretion (Tomita et al., 1999). To elucidate the structural interface 
of Mint1 and APP, our lab resolved the crystal structure of the Mint1 PTB domain bound 
to APP. The structure revealed that an adjacent helical C-terminal linker region (termed 
the “autoinhibitory helix”) intramolecularly inhibits the PTB domain of Mint1, blocking 
the APP binding site (Matos et al., 2012) [Figure 1.4]. Independently, the crystal 
structure of the Mint2 PTB domain bound to APP was also resolved, revealing the same 
autoinhibitory helix (Xie et al., 2012). Further analyses demonstrated the PTB domain is 
disrupted to a “high affinity” conformation by mutation of tyrosine 633 within the Mint1 
autoinhibitory helix to alanine [Figure 1.4]. In vitro experiments revealed that the “high 
affinity” Mint1 conformation led to enhanced APP binding and also increased Ab 




2012). These results suggest that Mint1 endogenously undergoes a conformational switch 
between a WT, autoinhibited conformation and a high affinity conformation that readily 
binds APP.  
Our lab also investigated the effects of Mint2 phosphorylation as a potential 
regulator of Mint/APP interaction. Our work exhibited that the endocytic sorting of APP 
is regulated by the Src-mediated phosphorylation of the N-terminus of Mint2, with 
internalized APP differentially sorting between autophagic and recycling trafficking 
pathways. The phosphomimetic Mint2 trafficked APP toward the autophagic pathway, 
leading to increased intracellular Ab42, while the phosphoresistant Mint2 trafficked APP 
to the recycling pathway back to the neuronal surface, increasing extracellular Ab42 
secretion (Chaufty et al., 2012). This work suggests that the Mint/APP interaction 
undergoes precise regulated control in the neuronal context, and further understanding of 
the mechanisms of regulation would provide valuable insights into APP/Mint biology.  
1.7 Thesis rationale 
 The prevalence of AD is increasing at an alarming rate worldwide and 
unfortunately there is only one provisionally approved disease-modifying treatment 
available (Alzheimer’s Association, 2021; Mullard, 2021). Numerous lines of evidence 
suggest that the generation of Aβ peptides through the proteolytic processing of APP is a 
key pathogenic event in AD (Selkoe and Hardy, 2016). Thus, targeting the production or 
accumulation of Ab is a viable strategy for treating AD, which is further supported by the 
newly provisionally approved Ab clearing drug, Aduhelm (Mullard, 2021). Aβ 




sequence located in the cytoplasmic region of APP (Koo and Squazzo, 1994; Perez et al., 
1999). Mints, a family of adaptor proteins, modulate APP endocytosis and amyloidogenic 
processing by directly binding to the YENPTY motif of APP (Borg et al., 1996; Sullivan 
et al., 2014). Triple Mint knockout neurons exhibit reduce APP internalization and Ab 
production, and loss of any one of the three Mint proteins in aging mouse models of AD 
decreases Aβ accumulation  (Ho et al., 2008; Sullivan et al., 2014). Mint proteins also 
interact via their PDZ domains with PS1, thereby promoting APP/PS1 colocalization and 
favoring Ab formation (Lau et al., 2000; Sullivan et al., 2014). Further, Mint proteins are 
upregulated in AD, and have been found to be associated with neuritic plaques (Jacobs et 
al., 2006; McLoughlin et al., 1999). We hypothesize that the APP-Mint interaction is a 
potential key therapeutic target to selectively reduce Aβ production in AD. However, the 
molecular mechanisms underlying the APP-Mint interaction and the effects on Aβ 
production are unclear. We previously demonstrated that Mint1 undergoes a 
conformational switch from an autoinhibited state to a high affinity APP binding state, 
and that this switch plays an important role in regulating APP processing (Matos et al., 
2012). Recent work with our collaborators also identified two residues in the Mint2 PTB 
backbone that are essential for APP binding (Bartling et al., 2021). As such, we have 
generated constitutive high affinity and low affinity Mint1 mutants that can enhance or 
interfere with APP binding, respectively. Using these constructs, we sought to determine 
how perturbing the APP-Mint1 interaction alters Mint1 and APP cellular dynamics. 
Therapeutically, we generated a novel cell-permeable APP mimetic peptide that 




attempted to elucidate the endogenous molecular switch that relieves Mint1 
autoinhibition so we can and leverage that knowledge to design an intervention that could 






Figure 1.1 The Ab hypothesis 
The sequence of major pathogenic events leading to AD, according to the Ab hypothesis 
(adapted from (Selkoe and Hardy, 2016). The dashed arrow signifies that Ab oligomers 
can directly induce inflammation and alter neuronal ionic homeostasis, leading to 
downstream neuronal dysfunction.  
  
Altered ionic homeostasis of neurons leads 
to oxidative injury 
Dominantly Inherited EOFAD
(0.5% of all AD cases)
Missense mutations in APP,  PSEN1, or 
PSEN2
Failure of Aβ clearance
(e.g ApoE4, suppressed inflammatory 
response, etc. ) 
Increased relative Aβ42 production over 
lifetime Gradually increasing brain Aβ42 levels 
Accumulation and oligomerization of 
Ab42 
Ab oligomers exert subtle toxic effects on 
synaptic function 
Deposition of Ab42 oligomers into diffuse 
plaques 
Microglia and astrocyte activation induces 
inflammatory response 
Altered kinase/phosphatase activity  
hyperphosphorylates tau, leading to tangles
Extensive synaptic dysfunction, 
neurotransmitter deficits, & neuronal loss 
Dementia 
Non-Dominant Forms of AD




Table 1.1: Phase 3 agents targeting Ab for the treatment of AD  
Adapted from (Cummings et al., 2021)   (ClinicalTrials.gov accessed Jan 5, 2021) 
 
*Note: Aducanumab was recently provisionally approved by the FDA on June 7, 2021  
  
Agent Mechanism of Action Sponsor 
Aducanumab* 
Monoclonal antibody designed 
to recognize soluble Ab 




Receptor for advanced 
glycation end products (RAGE) 
antagonist designed to reduce 
Ab transport into the brain 
vTv Therapeutics 
Gantenerumab Monoclonal antibody designed to recognize aggregated Ab  Roche 
Solanezumab 
Monoclonal antibody designed 





Monoclonal antibody directed 
at soluble Ab aggregates such 






 Figure 1.2 Non-amyloidogenic and amyloidogenic APP processing  
APP is a type I transmembrane protein with a large extracellular domain and a short 
intracellular domain containing an endocytic YENPTY motif. Non-amyloidogenic 
processing starts at the plasma membrane, with a-secretase cleaving within the Ab 
peptide (dark blue), releasing soluble APP alpha (sAPPa) and the shorter C-terminal 
fragment alpha (CTFa). CTFa is then cleaved by g-secretase, releasing the soluble p3 




is trafficked into b-secretase containing endosomes via clathrin mediated endocytosis. b-
secretase then cleaves APP, releasing soluble APP beta (sAPPb) and the C-terminal 
fragment beta (CTFb). CTFb is then cleaved by g-secretase, releasing Ab (dark blue) and 
the AICD. The Ab-containing vesicle can then be recycled back to the plasma membrane, 
releasing Ab into the extracellular space where it further aggregates into oligomers, 






Figure 1.3 Mint adaptor proteins 
The Mint family of adaptor proteins have an-isoform specific amino N-terminus and a 
conserved carboxyl C-terminus. Both Mints1 and 2 have an N-terminal Munc-18 
interacting domain (MID), while only Mint1 has a N-terminal calcium/calmodulin 
(CaM)-dependent serine protein kinase (CASK) interacting domain (CID). The C-
terminus of all three Mints contains a phosphotyrosine binding (PTB) domain that 
directly binds the endocytic YENPTY motif of APP. Each Mint isoform also has two 
contiguous postsynaptic density 95, discs-large /Zona-occludens-1 (PDZ) domains in 
their C-terminus that can bind to proteins such as Presenilin-1, voltage-gated calcium 






Figure 1.4 Autoinhibition of the Mint1 PTB domain 
A, Ribbon representation of the crystal structure (PDB ID: 4DBB) of the rat Mint1 PTB 
domain (orange) including the C-terminal autoinhibitory helix. The human Mint1 PTB 
domain structure (blue) is superimposed on the rat structure and the C-terminus of APP 
(green peptide) is shown complexed within the Mint1 PTB domain. The b-strands are 
labeled b1-7 and the a-helices are labeled a1-3. B, Ribbon and stick diagram illustrating 
how the a3 autoinhibitory helix interacts with the core PTB domain via hydrophobic 
amino acid side chain interactions. Carbon atoms are orange, nitrogen atoms are blue, and 






Figure 1.5 Experiments from our lab suggesting Mints facilitate APP endocytosis 
and Ab production  
Summary of experimental evidence from our lab, both in vivo and in vitro, suggesting 






CHAPTER TWO: Materials and methods 
2.1 Plasmids 
 All Mint constructs utilized in this study were derived from Rattus norvegicus 
cDNA, and all amino acid numbering reflects the amino acid sequences of rat Mint1 
(NCBI Reference Sequence: NP_113967.1) and rat Mint2 (NCBI Reference Sequence: 
NP_113968.1), unless otherwise specified. The pCMV5-huAPP695 construct was 
derived from Homo sapiens (NCBI Reference Sequence: NP_958817.1). For a 
comprehensive list of plasmids, see Table 2.1.  
2.2 Cloning expression vectors  
 Site-directed mutagenesis was performed using either QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies) or Q5 Site-Directed Mutagenesis Kit 
(New England Biolabs). Information regarding template plasmids, primer pairs (with 
altered nucleotides italicized and bolded), and the kit utilized for each reaction are listed 
in Table 2.2. 
To generate the pCMV5-huAPP695-RFP exon7 construct, the pCMV5-
huAPP695 plasmid was linearized using forward primer SMH 1622 5’-
GTTCCTACAACAGCAGCCAG-3’ and reverse primer SMH 1621 5’-
TCGAACCACCTCTTCCAC-3’. The red fluorescent protein (RFP) insert was then 
amplified from the pCAG-RFP plasmid using forward primer SMH 1620 5’-
GAAGAGGTGGTTCGAATGGCCTCCTCCGAGGAC-3’ and reverse primer SMH 
1623 5’-TGGCTGCTGTTGTAGGAACGGCGCCGGTGGAGGG-3’. The linearized 




EZ-10 Spin Column and DNA Extraction Kit) and combined following the Gibson 
Assembly Cloning Kit (New England Biolabs) protocol.  
The pEGFP-C3 full length (FL) rat Mint1 lacking exon 6 (DEx6) was generated 
using the NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs). Mint1 
exon 1-5 was amplified from the pEGFP-C3 FL rat Mint1 wildtype (WT) plasmid using 
forward primer SMH 2108 5’-
CGACGGTACCGCGGGCCCGGATGAACCACTTGGAGGGC-3’ and reverse primer 
SMH 2109 5’-CTTCAGGAGCCTTGATCCGGCTTACTGC-3’. Mint1 exon 7-
Cterminus was amplified using forward primer SMH 2110 5’- 
CCGGATCAAGGCTCCTGAAGGCGAATCTC-3’ and reverse primer SMH 2111 5’-
TCAGTTATCTAGATCCGGTGTCAGATGTAAACGGGCTG-3’. The Mint1 exon 1-5 
and Mint1 exon 7-Cterminus PCR products were agarose gel purified (Bio Basic EZ-10 
Spin Column and DNA Extraction Kit) and the pEGFP-C3 vector was linearized using a 
BAMHI-HF restriction digest. All three fragments (linearized pEGFP-C3, Mint1 exon1-
5, and Mint1 exon7-Cterminus) were then combined following the HiFi DNA Assembly 
Master Mix (New England Biolabs) protocol.  
To generate the pEGFP-C3 rat Mint1 PTB DEx6, Mint1 PTB exon 5 was 
amplified from pEGFP-C3-rat Mint1 PTB using forward primer SMH 2112 5’-
CGACGGTACCGCGGGCCCGGCCTGAAGACTTGATCGATG-3’ and reverse primer 
SMH 2113 5’-CTTCAGGAGCCTTGATCCGGCTTACTGC-3’. Mint1 exon7-PTB C-
terminus was amplified using forward primer SMH 2114 5’-




TCAGTTATCTAGATCCGGTGG-3’. Both PCR products were agarose gel purified 
(Bio Basic EZ-10 Spin Column and DNA Extraction Kit) and the pEGFP-C3 vector was 
linearized using a BAMHI-HF restriction digest. All three fragments (linearized pEGFP-
C3, Mint1 PTB exon5, and Mint1 exon7-PTB C-terminus) were then combined following 
the HiFi DNA Assembly Master Mix (New England Biolabs) protocol. All 
aforementioned cloned constructs were fully sequenced for validation. 
2.3 Mammalian cell culture and transfections 
 HEK293T (ATCC CRL-3216) cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; 
Atlanta Biologicals) and 1% Penicillin/Streptomycin (Gibco) at 37 °C in a 5% CO2 
incubator. At 60% confluency, HEK293T cells were transfected using FuGENE® 6 
(Roche) following the manufacturer’s protocol. All transfections utilized a 1:3 DNA 
plasmid: FuGENE®6 ratio.  
2.4 Co-Immunoprecipitation and PIP2 pull-down  
 HEK293T cells were lysed in immunoprecipitation buffer containing: 10 mM Tris 
HCl pH 8.0, 150 mM NaCl, 1 mM EDTA pH 8.0, and 1% Triton X-100, supplemented 
with protease (Aprotinin, Leupeptin, and Pepstatin; Sigma-Aldrich) and phosphatase 
inhibitors (100X phosphatase inhibitor cocktail; Bimake) 48 h following transfection. 
The cell lysate was sonicated and rotated for 30 min at 4°C and cleared with a 21,130 x g 
spin for 5 min. Protein extracts were incubated for 2 h with rotation at 4°C with the 
precipitating antibody, followed by overnight incubation at 4°C with either 10 μl of pre-




PIP2 beads (Echelon Biosciences). The resin was washed several times with 
immunoprecipitation buffer spinning at 700 x g for 30 s and precipitated proteins were 
eluted by boiling for 10 min in reducing 2X sample reducing buffer (0.1M Tris-HCL, pH 
6.8, 20% glycerol, 10% b-mercaptoethanol, 4% SDS, and 0.01% bromophenol blue), and 
resolved by SDS-PAGE.  
2.5 Western blotting  
 Cell lysates were collected in 2X sample reducing buffer, sonicated for 5 s, and 
then boiled for 10 min at 100°C. Lysates were then separated on SDS-PAGE gels and 
transferred to a nitrocellulose membrane (GE Healthcare). Membranes were blocked for 
1 h at room temperature with either 5% milk in Tris-buffered saline plus Tween (TBST) 
or Odyssey Blocking Buffer in phosphate-buffered saline (PBS) (LI-COR Biosciences) 
and incubated with primary antibodies overnight at 4°C. For a list of primary antibody 
dilutions and relevant buffers [Table 2.3]. Following primary antibody incubation, 
membranes were washed three times with either TBST or PBS and incubated in the 
appropriate secondary antibody conjugated to either IRDye®680RD- or IRDye®800CW 
(LI-COR Biosciences) at 1:20,000 in either 5% milk in TBST or Odyssey Blocking 
Buffer in PBS (LI-COR Biosciences) for 1 h at room temperature. Membranes were 
washed three times in the appropriate buffer (TBST or PBS) and imaged on the 
Odyssey®CLX Imaging System (LI-COR Biosciences).  
2.6 Mouse lines and primary neuronal cultures 
 Primary neuronal cultures were prepared using either CD1 (Charles River 




homozygous for floxed mutant alleles of all three Mint genes (fMint1/fMint1; 
fMint2/fMint2; fMint3/fMint3) (Ho et al., 2006). The MFTtg mouse line is the MFT line 
crossed with an APPswe/Presenilin1Dexon9 transgenic mouse line that overproduces 
human Ab (Jackson Laboratory stock #004462) (Ho et al., 2008).  The MFA mouse line 
is Mint1 and Mint3 double knockout with floxed Mint2 (Mint1-/-;fMint2/fMint2;Mint3-/-). 
Newborn pups of either sex were collected at postnatal day 0 (P0) and their dissociated 
brain tissue was trypsinized for 10 min at 37°C, triturated, and plated onto either Matrigel 
(Corning) coated glass coverslips or Matrigel (Corning) coated wells. Neuronal cultures 
were maintained in a 37°C humidified incubator with 5% CO2. To prevent glial 
proliferation, 4 µM Cytosine beta-D-arabinofuranoside hyrdrochloride (Ara-C; Sigma) 
was supplemented into the media on either 1 day in vitro (DIV) (hippocampal) or 2 DIV 
(cortical).  
2.7 Lentiviral infection of mouse neurons  
 Recombinant lentiviruses were produced by transfecting HEK293T cells using 
FuGENE®6 (Roche) with plasmids encoding viral enzymes and envelope proteins 
essential for packing of viral particles (pRSV-REV, pMDLg/pRRE, and pCMV-VSVG) 
with the addition of a shuttle vector encoding the gene of interest (pFUW). The media 
was changed to neuronal growth media 24 h after transfection and the conditioned media 
was collected, spun at 1,000 x g for 10min at 4°C, and filtered using a 0.45 µM filter (GE 
Healthcare) 48 h after transfection. Neurons were infected with lentiviral Cre 




Neurons were maintained in the same media/lentivirus mixture until analysis typically at 
15 DIV. 
2.8 Immunocytochemistry and image analysis 
 Primary hippocampal cultures were prepared from newborn mice and plated on 
Matrigel-treated (Corning) glass coverslips. Neurons were fixed with pre-warmed 4% 
paraformaldehyde (Electron Microscopy Sciences) at room temperature for 8 min, 
washed 3 times with PBS (Invitrogen), and permeabilized and blocked in 10% goat 
serum (Invitrogen) and 0.1% saponin (Sigma) in PBS for 1 h at room temperature. 
Neurons were incubated with primary antibodies (see Table 2.3) in blocking buffer (10% 
goat serum in PBS) overnight at 4°C. Neurons were washed 3 times with PBS and 
incubated with a secondary antibody conjugated to an Alexa FluorÒ (Invitrogen) in 
blocking buffer (10% goat serum in PBS) for 1 h at room temperature. Following PBS 
washes, the coverslips were mounted using ProLong Gold Antifade Mountant with DAPI 
(Invitrogen) and imaged using Z-stacks with a Carl Zeiss LSM 700 confocal microscope 
at 63X magnification. Corrected total cell fluorescence (CTCF) of maximum intensity 
projections was acquired using FIJI (National Institute of Health (NIH)).  Co-localization 
was quantified using IMARIS image analysis software (Oxford Instruments).  
2.9 Mint1 co-immunopreciptation for mass spectrometry analysis  
 Primary cortical cultures from CD1 newborn pups were prepared. At 2 DIV, 
neurons were infected with 20% Mint1 wild type (WT) lentivirus. At 13 DIV, one plate 
was treated with 25 µM glutamate for 10 min at 37°C. Neurons were washed with PBS 




mM Tris HCl pH 8.0, 150 mM NaCl, 1 mM EDTA pH 8.0, and 1% Triton X-100, 
supplemented with protease (Aprotinin, Leupeptin, and Pepstatin; Sigma-Aldrich) and 
phosphatase inhibitors (100X phosphatase inhibitor cocktail; Bimake). Samples were 
sonicated for 5 s, rotated in 4°C for 30 min, and the lysate was cleared with a 5 min 
21,130 x g spin. Protein extracts were incubated for 2 h with rotation at 4°C with the 
rabbit anti-GFP 1:250 (Synaptic Systems) followed by overnight incubation in 4°C with 
33 µl of pre-equilibrated Protein A Ultralink beads (Thermo Scientific). The resin was 
washed four times with immunoprecipitation buffer (same recipe as above, but without 
Triton-X-100), spinning at 700 x g for 30 s. The beads were transferred to a new 
Eppendorf twice during the washes to remove any proteins bound to the tubes. The last 
wash was completely aspirated, and the samples were transported on ice to Dr. Andrew 
Emili’s lab for phosphopeptide mass spectrometry analysis.   
2.10 Live-cell APP endocytosis assay  
 Primary MFT hippocampal cultures were prepared and plated onto Matrigel-
coated glass coverslips. Neurons were infected with 20% Cre recombinase lentivirus at 
day of plating and then with 5% Mint1 lentivirus on 2 DIV. At 15 DIV, live hippocampal 
cultures were incubated with an N-terminal APP antibody (mouse anti-APP 22C11, 
1:500; EMD Millipore) diluted in conditioned neuronal media for 15 min at room 
temperature. Neurons were washed with conditioned neuronal media twice to remove any 
unbound antibodies. Next, the neurons were treated with 25 µM glutamate (Man Lab) 
diluted in conditioned media to promote APP internalization and neurons were placed 




fixed with pre-warmed 4% paraformaldehyde (Electron Microscopy Sciences). Any APP 
antibodies remaining on the cell surface were quenched with a non-florescent goat anti-
mouse secondary antibody conjugated to horseradish peroxidase (HRP) (Cell Signaling) 
diluted in 10% goat serum (Invitrogen) in PBS for 1 h at room temperature. Neurons 
were then washed twice with PBS and permeabilized with 10% goat serum supplemented 
with 0.3% Triton-X-100 in PBS for 10 min at room temperature. Following another PBS 
wash, the permeabilized neurons were then blocked in 10% goat serum in PBS for 35 min 
at room temperature. Finally, the neurons were incubated with goat anti-mouse Alexa 
Fluor® 546 1:500 (Fisher Scientific) in 10% goat serum in PBS for 1 h at room 
temperature. Following three PBS washes, the coverslips were mounted using ProLong 
Gold Anti-fade Mountant with DAPI (Invitrogen) and imaged with a Carl Zeiss LSM 700 
confocal microscope at 63X magnification using Z-stacks. Corrected total cell 
fluorescence (CTCF) of maximum intensity projections was acquired using FIJI 
[National Institute of Health (NIH)].  
2.11 g-secretase APP cleavage assay 
 Primary MFTtg cortical neurons were cultured onto Matrigel (Corning) coated 
wells. On day of plating neurons were infected with Cre recombinase, and then infected 
with GFP-Mint1 lentivirus at 2 DIV. At 15 DIV, neurons were treated with 2 µM N-[N-
(3,5-Difluorophenacetyl-L-alanyl)]-(S)-phenylglycine t-butyl ester (DAPT, EMD 
Millipore) and placed back in the incubator for 24 h. Neurons were washed with pre-




neuronal growth media for the duration of the experiment, in which lysates were 
collected at 0, 4, 12, and 24 h after DAPT washout using 1X sample reducing buffer.  
2.12 Peptide treatment on primary mouse neurons 
Primary cortical neuronal cultures were prepared from newborn MFTtg mice carrying two 
alleles of the double transgene for mutant APP and presenilin-1. Peptides and DAPT, 
(EMD Millipore) were prepared as stock solutions in DMSO and diluted using PBS 
buffer according the desired final concentration in the assay. Neuronal cell medium was 
equilibrated to 500 μl before addition of peptide solutions. At 14 DIV, neurons were 
incubated with peptides, DAPT (γ-secretase inhibitor) and vehicle control (0.25% 
DMSO) for 24 h at 37°C. Neuronal cell conditioned media was collected and following a 
PBS wash, the cell lysate was collected in 2X sample reducing buffer.  
2.13 Ab42 ELISA  
To perform an Ab42 ELISA, conditioned neuronal media was diluted and handled 
according to the protocol of the Human Aβ42 Ultrasensitive ELISA Kit (Invitrogen) 
followed by colorimetric readout at 450 nm.  
2.14 Neuronal toxicity assays  
The CyQUANT™ Lactate Dehydrogenase (LDH) Cytotoxicity Assay (Thermo Fisher 
Scientific) was performed on conditioned neuronal media collected following peptide 
treatment. As a positive control, one set of neuronal wells were treated with the positive 
control lysis buffer provided with the kit. The media was handled according to the 





 For the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) toxicity assay, cortical neurons from 
newborn MFTtg mice were treated with a concentration curve of peptide at 15 DIV. The 
final concentration of DMSO in the highest treatment group (20 μM peptide) was 0.5% 
(v/v), so 0.5% (v/v) DMSO was used as the vehicle control. As a positive control, 
neurons were treated with 20% (v/v) DMSO, known to induce cytotoxicity. After 24 h 
incubation with the peptides and controls at 37°C, cell viability was measured by 
CellTiter96® AQueous One Solution Cell Proliferation Assay kit (Promega) according to 
the manufacturer’s protocol. 
2.15 Peptide pull-down from neuronal lysate 
 Peptides of interest (with a C-terminal Cys and a PEG2 linker) were loaded onto 
Dynabeads M-270 Epoxy Beads (Thermo Fischer Scientific) according the 
manufacturer’s protocol. The peptide-loaded beads were incubated, washed and eluted in 
Eppendorf tubes using a magnetic rack for separation. Primary neuronal cultures were 
prepared from transgenic MFA newborn mice and infected with lentivirus at 2 DIV. 
Control neurons containing Mint2 were infected with a lentiviral inactive Cre 
recombinase (DCre), while Mint2 knockout neurons were infected with active Cre 
recombinase (Cre). At 15 DIV, neurons were lysed in immunoprecipitation buffer 
containing: 10 mM Tris HCl pH 8.0, 150 mM NaCl, 1 mM EDTA pH 8.0, and 1% Triton 
X-100, supplemented with protease inhibitors. In brief, neuronal cell lysate was incubated 
with the loaded beads for 2 h at 37°C. After washing the beads 5 times with PBS buffer 




eluted with 15 μl 2X sample reducing buffer. The eluate was collected in clean tubes, 
boiled at 100°C for 5 min, and resolved by SDS-PAGE.  
2.16 Fluorescence polarization 
 The binding affinities were determined in a flat bottom black 384-well plate 
(Corning Life Science) using a Safire plate reader (Tecan). All experiments were 
conducted in 150 or 500 mM NaCl, 25 mM HEPES, 1% bovine serum albumin (BSA), 
pH 7.4 at 25°C and the fluorescence was measured at excitation/emission wavelength at 
530/580 nm. The instrumental Z-factor was adjusted to maximum fluorescence and the 
G-factor was calibrated to give an initial milli-polarization at 20. Fluorescence 
polarization assays were performed as saturation experiments using TAMRA-APP17-mer 
[(TAMRA)-NNG-QNGYENPTYKFFEQMQN] as probe at a concentration of 50 nM.   
2.17 Plasma stability assay  
Peptides were incubated in human plasma at 37 °C for up to 24 h. The peptides were 
extracted from the plasma at various time points and analyzed using ultra performance 
liquid chromotography (UPLC). 
2.18 Hepatic clearance assay 
Peptides were incubated in mouse hepatic microsomes supplemented with reduced β-
nicotinamide adenine dinucleotide 2′-phosphate (NADPH) and MgCl2 at 37 °C for up to 
60 min. The peptides were extracted from the microsomes at various time points and 




2.19 Electrophysiology  
 Miniature excitatory postsynaptic currents (mEPSCs) were recorded from primary 
murine neurons at 14-17 DIV using whole-cell voltage clamping. The external recording 
solution (140 mM NaCl, 3 mM KCL,1.5 mM MgCl2, 2.5 mM CaCl2,11 mM Glucose, 
and 10 mM HEPES; pH 7.4) was supplemented with 1 µM tetrodotoxin (TTX; Tocris), 
50 µM D-2-amino-5-phosphonovaleric acid (APV; Tocris) and 20 µM Bicuculline 
(Sigma). The internal electrode solution contained 130 mM Cs-MeSO3, 10 mM CsCl, 10 
mM HEPES, 4 mM MG-ATP, 0.3 mM Na-GTP, 0.2 mM EGTA, and 10 mM Na-
phosphocreatine; pH 7.2.  Recordings were collected using an Axiopatch 200A amplifier 
and 1440 Digitizer and final analysis was performed with pCLAMP10 software 
(Molecular Devices). 
2.20 Statistical analysis 
All statistical analyses were performed using Prism 9 software (GraphPad). To determine 
statistical significance, we used an ordinary one-way analysis of variance (ANOVA) 
coupled with either Sidak’s or Dunnett’s multiple comparisons test (specified on each 
figure). All graphs depict mean ± standard error of the mean (SEM) and significance is 





 Table 2.1 Plasmids 
Description Bacterial 
Resistance  
Source Experiment  
pCMV5-huAPP695 Ampicillin Angela Ho, Ph.D. Chapter 3 
WB 
pEGFP-Mint1 WT Kanamycin Angela Ho Ph.D. Chapter 3 
WB 
pEGFP-Mint1 High Affinity 
(Y633A) 
Kanamycin Cloned In-House Chapter 3 
WB 
pEGFP-Mint1 Low Affinity 
(Y549A/F610A) 
Kanamycin Cloned In-House Chapter 3 
WB 
pEGFP-Mint2 WT Kanamycin Angela Ho, Ph.D. Chapter 3 
WB 
pEGFP-Mint2 WTY460A/F521A Kanamycin Cloned In-House Chapter 3 
WB 
pEGFP-Mint1 9X 
phosphomimetic (T82E, Y169E, Y239E, 
S247D, S286D, T366E, S369D, Y371E, T372E) 




Kanamycin Cloned In-House Chapter 5 
WB 




pcmv5 Kinase deficient SRC 
(K295M) Chicken 




Pet28a-Mint1 WT PTB-C Kanamycin Tina Matos, Ph.D. Chapters 3,5 
Protein 
Purification 
Pet28a-Mint1 high affinity(Y633A) 
PTB-C 





















Ampicillin Uwe Beffert, Ph.D. Chapter 3 
Lentivirus 








Ampicillin Cloned In-House Chapter 3 
Lentivirus 
PFUW-GFP-Cre Ampicillin Angela Ho, Ph.D. Chapter 3 
Lentivirus 
PFUW-GFP-DCre Ampicillin Angela Ho, Ph.D. Chapter 3 
Lentivirus 




PFUW-GFP-Mint2 WTY460A/F521A Ampicillin Cloned In-House Chapter 3 
Lentivirus 
pCMV5-hAPLP1 Ampicillin Angela Ho, Ph.D. Appendix 
WB 
pCMV5-mAPLP2 Ampicillin Angela Ho, Ph.D. Appendix 
WB 
pCMV5-huAPP695-RFP exon7 Ampicillin Cloned In-House Appendix 
WB 
pFUW-huAPP695-RFP exon7 Ampicillin Cloned In-House Appendix 
Lentivirus, 
ICC 
pCMV5-rat CASK  Ampicillin Angela Ho, Ph.D. Appendix 
WB 
pEGFP-Mint2Y544A Kanamycin Cloned In-House Appendix 
WB 





pEGFP- Mint1 PTB WT Kanamycin Angela Ho, Ph.D. Appendix 
WB 
pEGFP- Mint1 PTB Acetylation 
Mimetic(K500Q,K503Q,K506Q,K507Q) 
Kanamycin Cloned In-House Appendix 
WB 
pEGFP- Mint1 PTB Acetylation 
Resistant(K500R,K503R,K506R,K507R) 
Kanamycin Cloned In-House Appendix 
WB 
pEGFP-Mint1 PTB D exon6  Kanamycin Cloned In-House Appendix 
WB 










Target Primers (5’à 3’) Kit 
pEGFP-C3 FL 
ratMint1WT Y633A 











Forward: SMH 1721 
CAGTCCATCGGGCAGGCCGCC
AGCGTTGCATACCAGGAG 





ratMint1 F610A Y549A 
Forward: SMH 1747 
GACCATTTCCGCCATCGCAGA
CATTG 







Forward: SMH 1814 
ACACCCCGACGCCCCTGGGCT
GCCAGCACCTG 






Forward: SMH 1810 
CTCGGCCAGCGAAGAGAGCG
GCTTCC 




ratMint1 T82E Y239E  
Forward: SMH 1804 
GCTGCACCACGAAGACGAGC
GCTCCG 







Forward: SMH 1812 
GAAAACCAGGGAAATCCGTTC
GCC 


























Forward: SMH 1907 
GAGCTCGCAGGATCTCGACAA
GGC 









Forward: SMH 1910 
CTACTCGGGCGAAGTCTACAC
GCAC 










Forward: SMH 1916 
CGACGGCGAGGATGACAGCC
CCG 











Forward: SMH 1920 
CCGCTCCAACGATCAGGAGA
ATGTGGAGGCCTCTCACCC 








Forward: SMH 2010 
AGCAGGAAGCAGGCTCCTGA
AGGCGAATCTC 









Forward: SMH 2012 
AGCAGGAAGAGAGCTCCTGA
AGGCGAATCTC 













Forward: SMH 2106 
AGCAGGCAGCAGGCTCCTGA
AGGCGAATCTC 










Forward: SMH 2107 
AGCAGGAGAAGAGCTCCTGA
AGGCGAATCTC 




pEGFP- C3 FL 
ratMint2 WT Y544A 









pEGFP- C3 FL 
ratMint2 WT F521A  
Forward: SMH 1725 
GTCAATTGGGCAGGCCGCCA
GTGTGGCCTACCAG 





ratMint2 F521A Y460A 
Forward: SMH 1727 
GCCTTGCGCACCATCTCCGCC
ATTGCAGACATTGGGAAC 









Table 2.3 Antibodies  
Name Dilution (WB buffer) Host Source Product Number 
4G10 
WB: 1:1,000 (LI-COR) 
IP: 1:500 
Mouse EMD Millipore 05-1050 
APLP1 WB: 1:1,000 (LI-COR) Rabbit Dr. Thomas Südhof T2263 
APLP2 WB: 1:500 (LI-COR) Rabbit Dr. Thomas Südhof T2264 
APP ICC: 1:500 Rabbit Abcam 126732 
APP 
22C11 WB: 1:500 (milk) Mouse EMD Millipore MAB348 
APP C-
terminal WB: 1:500 (milk) Rabbit Dr. Thomas Südhof U955 
CASK WB: 1:1,000 (LI-COR) Rabbit Abcam 3383 
Clathrin 
WB: 1:500 (LI-COR) 
IP: 1:250 
Mouse Santa Cruz Biotechnology Sc-12734 
GAPDH WB: 1:5,000 (LI-COR) Mouse Millipore MAB374 
GFP 
WB: 1:1,000 (LI-COR) 
IP: 1:250 
Rabbit Synaptic Systems 132-002 
GFP 
WB: 1:1,000 (LI-COR) 
ICC: 1:500 
Mouse Neuromab 75-131 
GM130 ICC: 1:1,000 Mouse BD Biosciences 610822 
Mint1 
WB: 1:500 (milk) 
IP: 1:250 
Rabbit Dr. Thomas Südhof P730 
Mint2 WB: 1:1,000 (milk) Rabbit Sigma-Aldrich M3319 





(9B11) WB: 1:1,000 (LI-COR) Mouse Cell Signaling 2276 
PSD-95 WB: 1:1,000 (LI-COR) Mouse Neuromab 75-028 
SRC 
(GD11) WB: 1:750 (LI-COR) Mouse Millipore 05184 
Synapsin 
WB: 1:1,000 (LI-COR) 
ICC: 1:500 
Rabbit Dr. Thomas Südhof P610 
TAT ICC: 1:250 Mouse Abcam 63957 
a-Tubulin WB: 1:5,000 (LI-COR) Mouse Cell Signaling 3873S 
b-Tubulin WB: 1:5,000 (LI-COR) Rabbit Biolegend 802001 







Figure 2.1 Schematic of the live cell APP endocytosis assay  
Simplified workflow of the APP live cell endocytosis assay. Panel 1, Live hippocampal 
cultures were incubated with an N-terminal APP antibody (mouse anti-APP 22C11, 
1:500; EMD Millipore) at room temperature (RT) for 15 min. Panel 2, Neurons were 
then treated with 25 µM glutamate (+Glu) and neurons were placed back in the 37°C 
incubator for 15 min to allow APP internalization. Panel 3, Surface APP antibodies were 
quenched with a non-fluorescent goat anti-mouse secondary antibody conjugated to 
horseradish peroxidase (HRP) for 1 h at room temperature (RT). Panel 4, Neurons were 
permeabilized and internalized APP antibody was labelled with goat anti-mouse Alexa 






CHAPTER THREE: Perturbing the Mint1-APP Interaction alters Mint1 
localization, APP endocytosis, and Ab production 
(Portions of this chapter were previously published in (Bartling et al., 2021). Figure 3.1A 
was performed by Thomas Jensen, Ph.D. from Kristian Strømgaard’s lab at the 
University of Copenhagen. The remaining experiments in this chapter (Figures 3.1B-E; 
and all panels in figure 3.2-3.6) were performed by Shawna Henry). 
3.1 Introduction 
 The endocytosis of APP into b-secretase containing endosomes is a critical early step 
in the amyloidogenic processing of APP (Koo and Squazzo, 1994). Mints, a family of 
adaptor proteins, modulate APP endocytosis and amyloidogenic processing by directly 
binding to the conserved endocytic YENPTY motif of APP (Borg et al., 1996; Sullivan et 
al., 2014). In fact, loss of any one of the three Mint proteins decreases Aβ production in 
aging mouse models of AD (Ho et al., 2008). Thus, investigating the dynamics and 
cellular consequences of the Mint-APP interaction is critical for understanding 
amyloidogenic APP processing associated with AD.  
 Extensive probing of both backbone H-bond and sidechain interactions between 
Mint2 and APP revealed two residues within the PTB domain of human Mint2, Y459 and 
F520, that are essential for APP binding. We then introduced the analogous point 
mutations onto full length rat Mint2, creating Mint2Y460/F521A [see Appendix Figure S1 
for the sequence alignment of human Mint2 and rat Mint2 sequences]. This rat 
Mint2Y460/F521A mutant bound less APP compared to Mint2 wild type and also reduced 




 Our lab previously identified a high affinity Mint1 mutant (Y633A) where 
autoinhibition of the PTB domain is relieved, increasing APP binding (Matos et al., 
2012). Informed by the discovery of the essential residues for APP-Mint2 binding, we 
then introduced the analogous mutations in rat Mint1, creating our low affinity 
(Mint1Y549A/F610A) mutant with reduced APP binding [see Appendix Figure S2 for the 
sequence alignment of rats Mint1, 2, and 3]. In this chapter, we will utilize these mutants 
to investigate how perturbing the Mint1-APP interaction alters Mint1 and APP cellular 
dynamics. We first verified the Mint mutant constructs by assaying their binding to APP 
in vitro by co-immunoprecipitation from HEK293T cells and quantitative fluorescence 
polarization (FP). Immunocytochemistry of the low and high affinity Mint1 mutants in 
primary mouse neurons revealed that Mint1 binding to APP is essential for Mint1’s Golgi 
and pre-synaptic localization. We then characterized the dynamics of amyloidogenic APP 
processing in primary mouse neurons infected with the Mint1 mutants. Mint1 low affinity 
decreased both APP endocytosis and Ab release in primary neurons.  
3.2 Results  
3.2.1 APP binding-deficient rat Mint2Y460A/F521A variant reduces Aβ42 levels in primary 
mouse neurons 
 To characterize the molecular resolution of the APP-Mint2 interaction, our 
collaborators performed extensive substitutional analyses of the Mint2 backbone. In total, 
they created 13 human Mint2-PTB domain alanine substitution mutants. They then 
employed FP using the C-terminal APP peptide (APPC-term) to investigate the 
consequences of each substitution on the APP-Mint2 interaction [see Figure 2d from 




>10-fold reduction in the APPC-term binding. Importantly, circular dichroism of each of 
the alanine mutants revealed no alterations in the secondary structure of the Mint2 PTB 
domain, suggesting these alterations in APP affinity were caused by the disruption of 
hydrophobic interactions with the APPC-term peptide [see Figure S10b from (Bartling et 
al., 2021)].  
 Using the alanine scan results, our collaborators combined the critical alanine 
mutations to synthesize a human Mint2 PTB variant with reduced APP binding. 
Introducing two mutations, Y459A and F520A, into human Mint2-PARM 
(hMint2Y459A/F520A) resulted in a significant 72-fold decrease in the APPC-term peptide 
binding affinity (Kd = 895 ± 43 μM) in the FP assay [Figure 3.1A]. To examine whether 
Mint2Y459A/F520A has a cellular effect on APP binding, we produced a full-length GFP-
tagged rat Mint2 (GFP-rMint2WT) and corresponding APP binding-deficient variant 
GFPrMint2Y460A/F521A (analogous to hMint2Y459A/F520A, Appendix Figure S1). We 
confirmed our FP results by co-transfecting HEK293T with full-length APP and either 
GFP-rMint2WT or GFP-rMint2Y460A/F521A and performing co-immunoprecipitation assays. 
APP co-immunoprecipitated with both GFP-rMint2WT [lane 5, Figure 3.1B] and GFP-
rMint2Y460A/F521A [lane 6, Figure 3.1B]; however, GFP-rMint2Y460A/F521A exhibited a 
significant 85% reduction in APP binding [Figure 3.1C].  
 Next, we examined the functional effect of an impaired interaction between APP 
and Mint2 on Aβ generation. We employed primary cortical neurons from the MFTtg 
mice, expressing mutant APP (APPswe) and presenilin-1 proteins (PS1ΔE9). We infected 




Expression of the GFP-rMint2Y460A/F521A variant was confirmed by Western blot analysis 
[Figure 3.1D]. We quantified the effect on Aβ42 levels released from primary neurons 
using ELISA on the neuronal conditioned medium. At 15 DIV, we observed a significant 
42% decrease in Aβ42 levels in neurons infected with GFPrMint2Y460A/F521A relative to 
neurons expressing only endogenous Mint2 [Figure 3.1E]. Together, our results confirm 
that APP interacts with the PTB domain of Mint2 and suggest that Mint2 plays a 
facilitative role in Aβ formation in our neuronal AD model.  
3.2.2 Mint1 high affinity and low affinity mutants exhibit altered cellular localization  
Previous work from our lab identified a single point mutation (Y633A) that 
relieves autoinhibition of the Mint1 PTB domain, increasing APP binding (Matos et al., 
2012). Leveraging this knowledge as well the essential residues for APP binding 
identified by our collaborators, we utilized site-directed mutagenesis to generate our 
GFP-tagged full length rat Mint1 high affinity (Mint1Y633A) and low affinity 
(Mint1Y549A/F610A) mutants [Figure 3.2A]. To determine whether these Mint1 mutants 
bind APP as expected in vitro, we co-transfected HEK293T with full-length APP and 
either GFP-Mint1 WT, GFP-Mint1 high affinity, or GFP-Mint1 low affinity and 
performed co-immunoprecipitation assays. Compared to GFP-Mint1 WT, GFP-Mint1 
high affinity pulled down significantly more APP and GFP-Mint1 low affinity pulled 
down significantly less [Figure 3.2B]. These alterations in binding affinity held true 
when performing a co-immunoprecipitation with the Mint1 mutants co-transfected with 
APP’s other family members, APLP1 and APLP2 [see Appendix Figure S3]. To further 




FP using a truncated PTB to C-terminus construct of Mint1 WT, high affinity, and low 
affinity. As expected, Mint1 high affinity bound APPC-term very well (Kd= 14.5 ± 0.74 
µM), a significant 19-fold change as compared to Mint1 WT (Kd= 282 ± 8.3 µM).  Mint1 
low affinity, with the two essential residues for APP binding mutated, exhibited an even 
lower affinity for APP than Mint1 WT, (Kd= 382 ± 12.5 µM) [Figure 3.2C].  
After confirming the Mint1 mutants interacted with APP as expected, we then 
wanted to investigate how specifically perturbing the Mint1-APP interaction via our point 
mutations would alter neuronal localization of Mint1. To accomplish this, we produced 
lentivirus to facilitate the expression of each of the GFP-tagged full length Mint1 mutants 
in primary neuronal cultures. Hippocampal MFA cultures, which lack endogenous Mint1, 
were infected on 2 DIV with the GFP-tagged mutants. Mints are pre-synaptic proteins 
involved in synaptic vesicle exocytosis (Ho et al., 2006), therefore, we immunostained 
infected hippocampal neurons with synapsin, a pre-synaptic marker. At 10 DIV, both 
GFP-Mint1 WT and GFP-Mint1 high affinity co-localized with synapsin. However, GFP-
Mint1 low affinity was diffuse, not localizing to the pre-synaptic puncta [Figure 3.3].  
Previous work established that Mints 1 and 2 localize to the Golgi in primary 
neurons (Biederer et al., 2002). Thus, we immunostained the infected hippocampal 
neurons with both GFP (to visualize Mint1) and a Golgi-maker (GM130) at 10 DIV. 
Interestingly, GFP-Mint1 high affinity co-localized to the Golgi slightly more than GFP-
Mint1 WT, and GFP-Mint1 low affinity lost its Golgi co-localization completely, 
diffusely labeling the soma [Figure 3.4A,B]. This suggests that the Mint1-APP 




assessed Golgi morphology, with a Golgi defined as “condensed” when it appeared 
compact and nearly circular in shape and “ribbon” when it was extended with multiple 
cisternae. Neurons infected with Mint1 high affinity tended to have a more condensed 
Golgi morphology [Figure 3.4C].   
3.2.3 Mint1 high affinity and low affinity mutants alter APP co-localization, endocytosis 
and Ab production  
 To determine whether our Mint1 mutants would exhibit altered co-localization 
with APP, we cultured hippocampal MFA neurons, which lack endogenous Mint1, and 
infected our GFP-tagged full length Mint1 mutants. Immunostaining with both GFP (to 
visualize Mint1) and a N-terminal APP antibody at 14 DIV revealed that Mint1 low 
affinity exhibited decreased Pearson’s co-localization with APP in both the soma and the 
processes [Figure 3.5].  
 To interrogate the functional consequences of our Mint1 mutants, we performed 
an APP live cell endocytosis assay. Utilizing this assay in the past, our lab illustrated that 
triple Mint knockout decreases APP endocytosis (Sullivan et al., 2014). We quantified 
intracellular APP in MFT cultured neurons lacking endogenous Mints (via Cre 
recombinase knockout) and rescued with our GFP-tagged Mint1 mutants [see Figure 2.1 
for the live cell endocytosis experimental paradigm]. Following glutamate application at 
15 DIV, neurons infected with Mint1 high affinity exhibited an ~24% and ~30% increase 
in internalized APP in the somas and processes compared to Mint1 WT, respectively 




in APP internalization as compared to Mint WT, ~27% and 22% in the soma and 
processes, respectively [Figure 3.6A].  
 As APP endocytosis is a critical step in Ab production, we next investigated 
whether these Mint1 mutants also altered Ab production in primary neurons. We knocked 
down Mints in primary MFTtg cortical neurons using our cre recombinase lentivirus. 
Then, we rescued the neurons with a full-length GFP-Mint1 WT, high affinity, or low 
affinity lentivirus. Knockdown of endogenous Mints as well as expression of the GFP-
Mint1 variants was confirmed by Western blot analysis [Figure 3.6B]. We quantified the 
effect on Aβ42 levels released from primary neurons using ELISA on the neuronal 
conditioned medium. At 14 DIV, aligning with previous data from our lab, triple Mint 
knockout neurons (Cre) exhibited a 47% decrease in Ab42 production compared to 
neurons expressing Mints (DCre). Interestingly, we observed a significant 36% decrease 
in Aβ42 levels in neurons infected with GFP-Mint1 low affinity relative to neurons 







Figure 3.1 APP binding deficient rat Mint2Y460A/F521A variant reduces Aβ42 levels in 
primary mouse neurons 
A, APPC-term peptide affinity for selected Mint2-PARM variants as determined by FP. 
Data are expressed as the mean + SEM (n = 3). The statistical significance was evaluated 
using one-way ANOVA with Dunnett’s multiple comparison test, **** p  ≤ 0.0001. B, 
GFPrMint2WT or GFP-rMint2Y460A/F521A were co-transfected with APP in HEK293T cells 
A B 




and subject to co-immunoprecipitation using a Mint2 antibody. Representative 
immunoblots for Mint2 and APP from immunoprecipitation (IP, top), total lysate (input, 
middle).a-tubulin served as a loading control. C, Quantification of APP bound to GFP-
rMint2WT and GFP-rMint2Y460A/F521A. Data were normalized to GFP-rMint2WT and 
expressed as the mean + SEM. The statistical significance was evaluated with the 
Student’s t-test, *** p  ≤ 0.001. (n = 4 independent experiments). D, Western blot for 
Mint2, APP, and α-tubulin from neuronal lysates carrying the APPswe/PS1ΔE9 mutation 
and infected with the lentiviral GFP-rMint2Y460A/F521A mutant. E, Aβ42 ELISA 
quantification of conditioned media from neurons overproducing Aβ shows reduced 
Aβ42 levels when neurons were infected with the GFPMint2Y460A/F521A mutant. Data were 
normalized to the endogenous Mint2WT control and expressed as the mean + SEM (n = 7 
biological replicates from two independent experiments). The statistical significance was 
evaluated using the Student’s t-test, *** p  ≤ 0.001. This figure is from (Bartling et al., 





  Kd mean ± SEM [µM], n=3 





APPC-term QNGYENPTYKFFEQMQN[d] 282 ± 8.3 14.5 ± 1.3 382 ± 12.5 
[a] maximum Mint1-PTB-C WT concentration in assay =52 µM [b] maximum Mint1-PTB-C high affinity 
concentration in assay = 32.8 μM; [c] maximum Mint1-PTB-C low concentration in assay = 44.8 μM; [d] 
N-terminally TAMRA-labeled separated with by a NNG linker 
 




A, Predicted conformation of the mutant Mint1 PTB domains, derived from the 
established crystal structure [orange = rat; blue = human structure] (PDB:4DBB) (Matos 
et al., 2012). Yellow stars represent the approximate locations of the high affinity 
(Y633A) and low affinity (Y549A and F610A) mutations and the APP C-terminal 
peptide is represented in green. B, GFP-Mint1WT, high affinity, or low affinity mutants 
were co-transfected with APP in HEK293T cells and subject to co-immunoprecipitation 
using a Mint1 antibody. Representative immunoblots for Mint1 and APP from 
immunoprecipitation (IP, top), total lysate (Input, middle) and control a-tubulin (bottom). 
The amount of immunoprecipitated APP was normalized to the amount of precipitated 
Mint1 and shown as percent Mint1 WT control. Data are expressed as the mean ± SEM 
(n = 4 independent experiments). The statistical significance was evaluated using one-
way ANOVA with Sidak’s multiple comparison test, ***p ≤ 0.001. C, APPC-term peptide 
affinity for the mutant Mint1 PTB to C-terminus constructs (included PPI domains 
depicted above the table) as determined by FP. (n= 1 independent experiment with 3 







Figure 3.3 Mint1 mutants alter pre-synaptic localization in primary mouse neurons  
Primary MFA neurons were infected with GFP-Mint1 mutants at 2 DIV. Neurons were 
fixed at 10 DIV, immunolabeled with GFP (Mint1) and pre-synaptic marker (synapsin), 
then mounted for fluorescence analysis. Representative images show GFP-Mint1 (green) 











A, Primary MFA neurons were infected with GFP-Mint1 mutants at 2 DIV. Neurons 
were fixed at 10 DIV, immunolabeled with GFP (Mint1) and Golgi marker (GM130), 
then mounted in ProLong Gold with DAPI (blue) for fluorescence analysis. 
Representative images show GFP-Mint1 (green) and Golgi staining (red). Scale bar = 10 
µm. B, Mander’s co-localization was quantified using Imaris and normalized to Mint1 
WT. Data are expressed as the mean ± SEM (n = 1 independent experiment, number of 
individual cells in the bottom of each bar). The statistical significance was evaluated 
using one-way ANOVA with Sidak’s multiple comparison test, *p ≤ 0.05, ***p ≤ 0.001. 
C, Percentage of condensed and ribbon Golgi in each treatment group, determined 
visually. Same neurons as analyzed in panel B. (n = 1 independent experiment, number of 





Figure 3.5 Mint1 mutants alter APP co-localization in primary mouse neurons 
A, Primary MFA neurons were infected with GFP-Mint1 mutants at 2 DIV. Neurons 
were fixed at 14 DIV, immunolabeled with GFP (Mint1) and an N-terminal APP 




Mint1 (green) and APP staining (red). Scale bars: soma = 10 µm; process = 5 µm B-C, 
Pearson’s co-localization was quantified in both the neuronal soma (B) and processes (C) 
using Imaris and normalized to Mint1 WT. Data are expressed as the mean ± SEM (n = 1 
independent experiment, number of individual cells in the bottom of each bar). The 
statistical significance was evaluated using one-way ANOVA with Sidak’s multiple 











A, Primary MFT mouse neurons were infected with Cre recombinase to knockout Mints 
and rescued with Mint1 mutant lentivirus. Representative images showing internalized 
APP (red) in both the soma (top) and processes (bottom) following 15 min glutamate 
stimulation at 15 DIV.  Scale bars: soma = 10 µm; process = 5 µm. B-C Quantification of 
the amount of internalized APP using corrected total cell fluorescence (El-Sharkawey, 
2016) in the neuronal soma (B) and processes (C), expressed as percent Mint1 WT. Data 
are expressed as the mean ± SEM (n = 2 independent experiment, number of individual 
cells in the bottom of each bar). The statistical significance was evaluated using one-way 
ANOVA with Sidak’s multiple comparison test, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. D, 
Western blot illustrating Mint protein expression in neurons treated with inactive Cre 
recombinase (DCre) or active Cre recombinase lentivirus. GFP-Mint1 expression levels 
indicate lentiviral rescue with the GFP-Mint1 mutants in the MFTtg primary neurons is 
similar to endogenous Mint1 expression. E, Aβ42 ELISA quantification of conditioned 
media from 14 DIV MFTtg shows reduced Aβ42 levels when neurons were infected with 
GFP-Mint1 low affinity. Data were normalized to DCre control, which expressed all three 
Mint isoforms, and expressed as the mean ± SEM (n = 3 biological replicates from one 
independent experiment). The statistical significance was evaluated using one-way 






Our collaborators performed extensive biochemical characterization of the human 
Mint2 PTB-APP PPI and identified two essential residues (Y459 and F520) that facilitate 
APP binding (Bartling et al., 2021). We then introduced the analogous alanine point 
mutations into full-length rat Mint2Y450A/F521A. This non-binding mutant exhibited reduced 
APP binding in HEK293T cells as well as decreased Ab production when infected into 
primary MFTtg neurons. The ability of Mint2Y450A/F521A to decrease Ab42 production in 
the presence of endogenous Mints may be explained by Mint2’s tendency to dimerize. 
Previous work from our lab illustrated that Mint2 dimerizes via its PDZ domains. Thus, it 
is possible that the non-binding Mint2Y450A/F521A mutant dimerized with endogenous 
Mint2, impairing the dimer complex and acting in a dominant-negative manner. 
Our lab has extensively studied the autoinhibition of Mint1’s PTB domain, 
identifying a single point mutation (Y633A) that relieved autoinhibition and increased 
APP binding (Matos et al., 2012). We have since introduced the Y633A point mutation 
into full-length Mint1, creating a mutant with high-affinity binding to APP. Leveraging 
the biochemical characterization of the Mint2-APP interaction performed by our 
collaborators, we introduced the analogous alanine mutations in full-length rat Mint1 
(Y549A and F610A), generating a Mint1 mutant with low affinity binding to APP. Co-
immunoprecipitation from HEK293T cells confirmed that the Mint1 high affinity and 
low affinity mutants bound more and less APP, respectively. Immunocytochemistry in 
primary neurons revealed that Mint1 low affinity lost its pre-synaptic and Golgi 




affinity exhibited increased APP endocytosis as well as Ab production, while Mint1 low 
affinity decreased both APP endocytosis and Ab release.  
Mints typically localize to both the pre-synaptic compartment and Golgi in 
primary neurons (Biederer et al., 2002; Okamoto et al., 2000). The diffuse, non-specific 
localization of Mint1 low affinity in primary neurons suggests that Mint1’s pre-synaptic 
and Golgi localization is dependent on its interaction with APP. This is supported by 
previous work in HeLa cells that revealed that Mint3 was recruited to the Golgi in an 
APP-dependent manner (Caster and Kahn, 2013). Work from our lab using a truncated 
Mint2 construct lacking its PDZ domains also mislocalized, not concentrating at the 
Golgi (Lin et al., 2019). Together, these experiments suggest that Mint’s neuronal 
localization is heavily dependent on its protein-protein interactions. Mints are a cytosolic 
protein, so they are not trafficked through the secretory pathway. It is proposed that 
cytosolic proteins destined for the axon assemble into multi-protein complexes that are 
then directly or indirectly carried by motors to their destination (Scott et al., 2011). In 
fact, Munc-18, another cytosolic pre-synaptic protein, forms a binary complex with the 
transmembrane protein syntaxin-1 to traffic down axons (Cijsouw et al., 2014). It is 
possible that Mints utilize a similar method, binding to transmembrane binding partners, 
such as APP, to drive its localization.  
As Mints play a role in presynaptic neurotransmitter release, the mislocalization 
of Mint1 low affinity away from the pre-synaptic compartment would most likely alter 
synaptic transmission (Ho et al., 2006). Preliminary electrophysiology data in neurons 




postsynaptic currents (mEPSCs) [see Appendix Figure S4]. However, more extensive 
experiments would be necessary to ascertain the total effect on synaptic transmission. 
Further, in order to terse apart whether these changes in transmission are APP dependent, 
we could infect the Mint1 mutants in APP knockout neurons and perform 
electrophysiology. 
The Mint1 high affinity mutant increased its localization to the Golgi, most likely 
driven by its increased affinity for the C-terminus of APP (which is available in the 
neuronal cytosol as APP is trafficking through the Golgi). The Golgi has been implicated 
as a site for amyloidogenic APP processing, so it is possible that Mints could also 
function at the Golgi in amyloidogenic APP processing (Fourriere and Gleeson, 2021). In 
the presence of Mint1 high affinity, a greater number of cells had a condensed Golgi 
morphology [Figure 3.3C]. Interestingly, this is similar to the Golgi phenotype seen in 
primary neuron knockouts of another pre-synaptic protein, Munc-18. In Munc-18-1 
knockouts, the Golgi exhibited a more condensed phenotype with a smaller area (Santos 
et al., 2017). Alterations in Golgi morphology are a preclinical feature that occurs before 
neurodegeneration associated with AD (Dal Canto, 1996; Stieber et al., 1996). More 
extensive characterization of the Golgi, using an established metric such as area, will be 
necessary to quantitatively assess the morphological changes that occur in the presence of 
Mint1 mutants.  
Previous work from our lab revealed that triple Mint knockout neurons exhibit no 
significant alterations APP localization, total APP, or APP surface levels, which suggests 




al., 2008). In fact, Kinesin-1, the motor protein, has been implicated in the axonal 
trafficking of APP (Kamal et al., 2000). Our immunocytochemistry revealed that neurons 
infected with Mint1 low affinity exhibit less punctate APP staining [Figure 3.5]. 
However, we did not quantitatively analyze this change, and it is difficult to determine 
because APP labels so ubiquitously through the neuron. To interrogate APP trafficking 
dynamics, we could measure APP surface levels via a surface biotinylation assay or non-
permeabilized immunocytochemistry in primary neurons. It is possible that Mints may 
alter the subcellular localization of APP in axon and not the initial trafficking of APP to 
the plasma membrane. Thus, a more extensive interrogation of localization using various 
subcellular markers could be useful. We also cloned a novel APP695 plasmid tagged with 
RFP within the sequence of APP [in the place of exon 7, because exons 7 and 8 are 
normally spliced out in the shorter 695 brain-specific APP isoform]. This novel 
huAPP695-RFP exon7 mutant is uniquely poised to study APP trafficking, because a C-
terminal tag that would occlude APP’s interaction with its adaptor proteins and an N-
terminal tag would be cleaved off with the signaling peptide as APP is trafficked through 
the secretory pathway [Appendix Figure S5].  
In agreement with previous work from our lab, the Mint1 low affinity mutant 
caused a significant decrease in both APP endocytosis and Ab production. These results 
further support that Mints play a facilitative role in the endocytosis and amyloidogenic 
processing of APP. Our novel Mint1 mutants, which employ point mutations to alter APP 
affinity in a full length Mint1 context, provide a unique tool to terse apart the specific 




relied on Mint1 knockouts, but this strategy is flawed when studying an adaptor protein 
with such a complex PPI network (Sullivan et al., 2014; Xie et al., 2005). Our low 
affinity mutant, which presumably only alters hydrophobic interactions with APP and not 
the overall structure of the Mint PTB domain, specifically ablates APP binding while still 
allowing Mint to facilitate its other PPIs. Thus, the Mint1 low affinity mutant reveals the 




CHAPTER FOUR: Targeting the APP-Mint protein-protein interaction with a 
peptide-based inhibitor reduces Ab formation 
(This chapter was previously published in (Bartling et al., 2021). Portions of this chapter 
were performed by Christian Bartling,Ph.D. from Kristian Strømgaard’s lab at the 
University of Copenhagen (Figure 4.2B,C; Figure 4.3A,B). The remaining experiments in 
this chapter (Figure 4.2D, 4.3C, and all panels in 4.4 and 4.5) were performed by 
Shawna Henry.) 
4.1 Introduction  
The production of Ab, which results from the sequential cleavage of APP by b- 
and g- secretase, is a key pathogenic event in AD (Selkoe and Hardy, 2016). Over the 
years a number of AD therapeutics have targeted pathogenic Ab. Strategies included: (1) 
reducing Ab production (via targeting the b- or g-secretase) or (2) promoting the 
clearance of existing Ab peptide and its aggregates (Panza et al., 2019). Unfortunately, 
drugs aimed at inhibiting b-secretase activity, such as verubecestat and atabecestat, and 
those aimed at inhibiting g-secretase activity, such as semagacestat and avagacestat, were 
unable to progress past Phase 3 clinical trials. Both b- and g-secretase cleave numerous 
target substrates, so there are a number of potential off-target effects when inhibiting 
theses secretases (Maia and Sousa, 2019; Selkoe, 2019). For this reason, the secretases 
are not attractive targets for AD therapeutics. In contrast, a number of immunotherapies 
aimed at promoting the clearance of Ab and its aggregates have advanced to stage 3 




monoclonal antibody aimed at clearing soluble Ab oligomers and insoluble Ab fibrils, 
was recently provisionally approved by the FDA (Mullard, 2021). This approval 
represents the first ever FDA approved disease-modifying treatment for AD, and it 
underscores the efficacy of targeting Ab as an AD therapeutic target.  
In this chapter, we will explore the Mint-APP interaction as a potential 
therapeutic target for AD. Previous in vitro work from our lab established that Mints 
facilitate APP endocytosis, co-localization with PS1, and Ab production (Sullivan et al., 
2014). In vivo, knockout of Mint proteins in an aging AD mouse model decreased Ab 
accumulation, suggesting that Mints can provide a novel point of intervention in AD (Ho 
et al., 2008). To exploit this novel therapeutic target, we generated a cell-permeable APP 
mimetic peptide that interferes with the APP-Mint interaction. This high affinity APP 
mimetic peptide was designed to outcompete endogenous APP binding, with a 46-fold 
improved affinity to Mint2. We hypothesized that introducing this peptide would prevent 
APP-Mint binding, which would consequently decrease APP endocytosis and subsequent 
Ab production [Figure 4.1]. Introduction of a cell-permeable version of the peptide onto 
primary neuronal cultures followed by immunocytochemistry confirmed the peptide’s 
cell permeability. Further in vitro characterization revealed that 24-hour peptide 








Figure 4.1 Proposed model of reducing Ab production via inhibiting the APP-Mint 
interaction with a peptide-based inhibitor  
A, The PTB domain of Mint proteins (Mint2 depicted above) interacts directly with the 






production (Borg et al., 1996; Sullivan et al., 2014). Mints also interact with PS1, 
facilitating the intracellular co-localization of APP and PS1 (Sullivan et al., 2014). B, A 
cell permeable APP mimetic peptide (TAT-APPMP), designed to selectively bind with 
high affinity to the PTB domain of Mint2, will inhibit the APP-Mint interaction, 





4.2 Results  
4.2.1 APP mimetic peptide (APPMP) binds Mint2 with high affinity 
 We first developed a potent peptide to disrupt the APP-Mint2 PPI. Using the 
human wild type APP C-terminus (755-NGYENPTYKFFE-766) as a template, we 
prepared a series of APP wild type (APPWT) peptide variants containing single 
substitutions of both canonical (cAAs) and noncanonical amino acids (ncAAs). We 
identified six positions (N755, Y757, Y762, F764, F765, and E766) in the APPWT peptide 
at which substitutions to cAAs or ncAAs either improved the affinity or were expected to 
improve the proteolytic stability of the peptide. The resulting high affinity APP mimetic 
peptide (APPMP) bound to the purified Mint2 PTB-ARM domain with nanomolar affinity 
(Kd = 53 ± 2 nM) as determined by isothermal titration calorimetry (ITC), a 46-fold 
improved affinity compared to APPWT (Kd = 2.4 μM) [Figure 4.2A-C]. To determine 
whether APPMP binds full-length Mint2, APPMP and APPWT were conjugated to epoxy-
coated magnetic beads via an N-terminal Cys-PEG linker and incubated with primary 
mouse neuronal lysate from wild-type or Mint2 knockout mutants for a pull-down assay. 
Western blot analysis confirmed the APPMP bound endogenous Mint2 with higher affinity 
[lane 2, Figure 4.2D] compared to the APPWT peptide, which had a much lower affinity 
to Mint2 [lane 3, Figure 4.2D].  
4.2.2 APPMP is proteolytically stable and TAT-APPMP is cell permeable  
 To investigate the proteolytic stability of the APPMP, we performed an in vitro 
plasma stability assay. Peptides were incubated in human plasma at 37°C for up to 24 h. 




ultra performance liquid chromatography (UPLC). The APPMP was found to be 
proteolytically stable over 24 h (half-life ≥ 1440 min) in human plasma, while the APPWT 
peptide exhibited a half-life of <30 min [Figure 4.3A]. We also examined the rate of 
metabolism through cytochrome P450 enzymes using mouse liver microsomes to 
determine the in vitro hepatic clearance of APPMP compared to APPWT. We found the 
APPWT peptide was cleared fast [CL(int) = 15.4 ± 2.5 μl/(mg min)] while APPMP was not 
metabolized over 60 min [CL(int) = 0.0 ± 0.8 μl/(mg min)] [Figure 4.3B]. The APPMP 
was proteolytically stable in plasma as well as metabolically stable when tested in the 
hepatic clearance assay, supporting its promise as a therapeutic peptide.  
 In order to facilitate the cell-permeability of the APPMP, we conjugated the cell-
penetrating peptide (CPP) TAT47−57 (KKRRQRRR) to its N-terminus. TAT is a widely 
used CPP and was recently demonstrated to be compatible with late-stage clinical 
development in two Phase 3 clinical trials (ESCAPE and FRONTIER), rendering TAT 
the most advanced CPP tag in the clinic (Hill et al., 2020; Morrison et al., 2015). We 
treated MFTtg primary neurons with either 10 µM untagged APPMP or 5 µM TAT-APPMP 
for 24 h on 7 DIV. Immunofluorescence staining with an anti-TAT antibody exhibited 
fluorescence in the cytoplasm and processes of primary MFTtg  hippocampal neurons 
treated with TAT-APPMP, indicating intracellular peptide uptake. The control neurons, 
treated with the APPMP lacking the TAT-tag, did not exhibit fluorescence, as expected 




4.2.3 Cell-permeable variants of APPMP decrease Ab with minimal toxicity in vitro 
 To investigate potential peptide toxicity, we treated MFTtg cortical neurons with 
varying concentrations of TAT-APPMP, TAT-APPWT, or untagged APPMP on 7 DIV. After 
24 h of peptide treatment, we performed an MTS assay, which provides a colorimetric 
readout of metabolic activity. TAT-APPWT and APPMP exhibited no adverse effects, 
while TAT-APPMP affected cell viability at 20 μM (75%) but had no measurable effect at 
10 μM [Figure 4.4A-C].  
Using the MTS toxicity results to inform our peptide dosing, 14 DIV MFTtg 
primary cortical neurons were incubated for 24 h with peptides TAT-APPMP, TAT-
APPWT, and APPMP. ELISA quantification of Aβ42 from the conditioned medium 
revealed that 10 μM TAT-APPMP led to a 44% reduction of Aβ42 levels relative to 
vehicle control. In contrast, 50 µM TAT-APPWT and 10 μM APPMP did not affect Aβ42 
levels. High-affinity γ-secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-Sphenyl-glycine tert-butyl ester or LY-374973) served as a positive control, 
reducing Aβ42 levels by 47% [Figure 4.4D].  
 In addition, we assessed the effect of TAT-APPMP on cellular integrity by 
quantifying lactate dehydrogenase (LDH) release (a proxy for cytotoxicity) in the same 
conditioned medium used for the aforementioned ELISA. We found low LDH levels for 
both DAPT and TAT-APPMP treated neurons relative to vehicle control, indicating that 
the effect of peptide TAT-APPMP on Aβ production is not due to cellular toxicity [Figure 
4.4E]. Furthermore, p-value analysis found no significant difference between the vehicle 




 To expand our study, we also synthesized four additional variants of APPMP 
containing different CPPs attached to the N-terminus: mixTAT (rRrGrKkrK- APPMP), 
polyArg (RRRRRRRRR- APPMP) (Tünnemann et al., 2008), D-SynB3 (frrrsyslrr- 
APPMP) (Rousselle et al., 2003), and MiniAp4 (cyclo(DLATEPAK(Dap)- APPMP) (Oller-
Salvia et al., 2016). Next, we determined the highest treatment concentration with no 
adverse effect on cell viability using the MTS assay. Following 24 h treatment on 7 DIV 
MFTtg neurons, mixTAT-APPMP and polyArg-APPMP were tolerated at concentrations of 
5 and 7.5 μM, respectively, while MiniAp4 APPMP exhibited no toxicity [Figure 4.5A-
C]. Peptide D-SynB3-APPMP was poorly soluble and not further tested. The peptides’ 
effect on Aβ formation was evaluated analogously to that of peptide TAT-APPMP. The 
quantification of Aβ42 from the conditioned medium of primary neurons revealed that 
incubation with 5 µM mixTAT-APPMP and 5 µM polyArg- APPMP reduced Aβ42 levels 
by 80 and 84%, respectively. In contrast, incubation with 10 µM MiniAp4- APPMP did 
not affect Aβ42 production [Figure 4.5D]. Of note, we detected a small but significant 
increase in LDH activity following incubation with 5 µM mixTAT- APPMP compared to 
the vehicle control [Figure 4.5E]. Consequently, polyArg-APPMP, which reduced Aβ42 
production at a lower concentration (5 μM) with minimal cellular toxicity, is a promising 






Figure 4.2 APP mimetic peptide (APPMP) binds Mint2 with high affinity 
A, Structural representation of the interaction between rat Mint2 PTB-ARM (PARM) 
domain (365-557 aa) (gray) and APP peptide that includes the YENPTY endocytic motif 
(blue) – adapted from (Xie et al., 2012) (PDB ID: 3SV1). B, Schematic structure of the 
APPMP. C, Representative ITC of titrating Mint2-PARM with APPMP raw heat signature 
(top) and integrated molar heat release (bottom). D, Representative pull down of Mint2 
from MFA neuronal cell lysate (15 DIV). Lanes 1–3: control neurons expressing Mint2. 
Lanes 4–6: Cre-recombinase mediated Mint2 knockout neurons. The eluent was resolved 





Figure 4.3 APPMP is proteolytically stable and TAT-APPMP cell permeable 
A, In vitro plasma stability of APPMP (blue) and the APPWT peptide (black) including 
buffer control for the APPWT peptide (circles); data are expressed as the mean ± SEM 
(n = 3).  B, In vitro hepatic clearance of APPMP (blue) and the APPWT peptide (black) 
including propranolol positive control (circles, n = 1); data are expressed as the mean ± 
SEM (n = 3). C, Representative TAT immunostaining of 7 DIV MFTtg neurons incubated 
with 10 µM APPMP or 5 µM TAT-APPMP for 24 h. TAT immunoreactivity (green) and 
DAPI nuclear staining (blue) are shown, white dashed lines outline the cell body. Scale 





Figure 4.4 TAT-APPMP reduces Ab production in vitro with minimal toxicity  
A-C, MTS assay following 24 h treatment of 7 DIV MFTtg neurons with varying 
concentrations of (A) TAT-APPMP; (B) TAT-APPWT; and (C) APPMP (no CPP). Data 




for all peptides) and shown as individual points mean + SEM (n = 3 biological 
replicates). Statistical significance was evaluated against untreated using one-way 
ANOVA with Dunnett’s multiple comparison test, *** p ≤ 0.001. D, Aβ42 ELISA 
quantification from conditioned media of 14 DIV MFTtg neurons treated with peptide for 
24 h; data are normalized to the vehicle control and expressed as the mean ± SEM (n = 3 
independent experiments, n = 10 biological replicates for the vehicle, DAPT, and 10 µM 
TAT-APPMP.) Independent experiments are represented by different shapes. Statistical 
significance evaluated using one-way ANOVA with Dunnett’s multiple comparison test, 
***p ≤ 0.001. E, LDH levels from conditioned medium of cultured MFTtg neurons 
collected after 24 h treatment with DAPT and 10 µM TAT-APPMP. Maximum LDH 
represents the maximum amount of LDH released from neurons lysed using detergent. 
Individual data points in (E) correspond to data in panel (D) (circles = same assay). Data 
are expressed as %LDH normalized to vehicle control and shown as the mean ± SEM. 
Statistical significance was evaluated using one-way ANOVA with Sidak’s multiple 







Figure 4.5 Cell penetrating peptide examination: PolyArg-APPMP is most efficient at 




A-C, MTS assay following 24 h treatment of 7 DIV MFTtg neurons with varying 
concentrations of (A) mixTAT-APPMP; (B) polyArg-APPMP; and (C) MiniAP4-APPMP. 
Data expressed as % viability normalized to untreated neurons (untreated; same reference 
used for all peptides) and shown as individual points mean + SEM (n = 3 biological 
replicates), statistical significance was evaluated against untreated using one-way 
ANOVA with Dunnett’s multiple comparison test, ** p ≤ 0.01, *** p ≤ 0.001. D, Aβ42 
ELISA quantification from the conditioned medium of cultured DIV 14 MFTtg neurons 
incubated with peptides for 24 h. Data shown as individual points as well as mean ± SEM 
(n = 3 biological replicates). Statistical significance evaluated using one-way ANOVA 
with Dunnett’s multiple comparison test, ***p ≤ 0.001.E, LDH levels from conditioned 
medium of cultured MFTtg neurons collected after 24 h treatment with DAPT or CPP-
APPMP. Spike LDH represents a positive control of purified LDH provided with the kit. 
Data are expressed as %LDH normalized to vehicle control and shown as the mean ± 
SEM. (n = 3 biological replicates) Statistical significance was evaluated using one-way 






 Using the C-terminal APPWT peptide as a template, we developed a high-affinity, 
proteolytically stable cyclic APPMP. We demonstrated that introducing noncanonical 
amino acids, N-methylation, and D-amino acids into a macrocyclic peptide scaffold 
provided a vast (46-fold) improvement in affinity for Mint2. These peptide optimizations 
also improved plasma stability and slowed hepatic clearance relative to the APPWT 
peptide. Notably, compared to APPWT, APPMP exhibited an enhanced affinity to robustly 
pull down full-length Mint2 from neuronal lysate. We confirmed that targeting the 
Mint2-APP interaction with cell permeable variants of APPMP (TAT-APPMP and 
polyArg-APPMP) significantly reduced Aβ42 formation with minimal toxicity in vitro, 
whereas cell-permeable TAT-APPWT peptide had no effect on Aβ42 formation. The 
observation that TAT-APPWT has no effect on Aβ42 formation is in excellent agreement 
with the pull-down results and highlights the importance of ligand optimization. Peptides 
TAT-APPMP and polyArg-APPMP therefore provide first proof-of concept evidence that 
targeting a direct interaction partner of APP affects its metabolism and Aβ formation. 
Furthermore, the comparison of different CPP tags indicates that the selection is critical 
and affects not only efficacy but also neuronal viability. Here, the combined analysis of 
LDH levels and Aβ42 reduction suggests that polyArg-APPMP is superior to TAT APPMP.  
Previous work has shown the convergence of APP and BACE-1 in acidic 
endosomes is a critical step in Ab production (Koo and Squazzo, 1994). In fact, human 
AD pyramidal neurons exhibit larger endosomal volumes than normal, implying an 




revealed that early increases in Ab coincide with abnormal endosomes in neurons, and 
that Ab co-localizes to these Rab-5 positive early endosomes in AD brains (Cataldo et al., 
2004). The importance of APP endocytosis for amyloidogenic processing is further 
supported by recent GWAS studies, which identified a group of susceptibility genes 
implicated in endocytosis (Karch and Goate, 2015).  
In vivo, preventing APP endocytosis via introducing a dominant-negative 
dynamin (Cirrito et al., 2008) or deleting the endocytic YENPTY motif in APP’s C-
terminus reduces Ab production (Ring et al., 2007). However, these strategies are not 
translatable to the clinic, and a more targeted approach would be necessary to avoid 
deleterious off-target effects. There is precedence for pharmacological treatment aimed at 
preventing APP localization in acidic b-secretase containing endosomes as an AD 
therapeutic strategy. In fact, one-such target was the neuronal retromer, which traffics 
APP away from endosomes. Introducing pharmacological chaperones stabilizing the 
retromer complex onto mouse neurons successfully shifted APP away from the 
endosome, decreasing the pathogenic processing of APP (Mecozzi et al., 2014). This 
work supports that diverting APP away from b-secretase containing endosomes is a 
viable strategy for reducing Ab.  
As such, pharmacological approaches modulating direct binding partners involved 
in APP trafficking and processing are promising alternatives to currently pursued 
therapies. For years, our lab has studied and characterized a potentially novel target for 
AD therapeutics: Mints. We have illustrated via neuronal knockout studies in vitro that 




knockouts were also shown to affect APP endocytosis specifically, as evidenced by no 
changes in the internalization of the excitatory glutamate AMPA-type receptor, GluR1 
This study also illustrated that Mints facilitate the endocytosis of PS1, favoring the 
intracellular co-localization of APP and PS1(Sullivan et al., 2014). Thus, inhibition of the 
Mint2-APP PPI by our cell permeable APPMP compounds could either specifically reduce 
APP endocytosis or prevent the formation of the tertiary protein complex comprising 
APP (C99), Mint2, and PS1. Both avenues would ultimately result in reduced Aβ 
formation. The present study provides evidence that modulation of the APP-Mint2 PPI 
using a cell-permeable APPMP serves as a pharmacological strategy to reduce pathologic 
Aβ levels in connection with AD. 
Although numerous studies have examined the biological importance of Mint 
proteins, particularly with regard to Aβ formation in the context of AD, these studies 
have been informative but contradictory (Ho et al., 2008; Kondo et al., 2010; Saito et al., 
2008; Xie et al., 2005). The work presented here further supports that Mints facilitate 
APP endocytosis and Ab production, because interfering with the APP-Mint interaction 
(using a mimetic peptide) decreased Ab production. Our strategy, which selectively 
inhibits APP binding to the PTB domain of Mint proteins, would likely not interfere with 
the critical function of Mint proteins in synaptic vesicle exocytosis because that is 
mediated through Mint’s other PPI domains (Ho et al., 2006; Okamoto and Sudhof, 
1997). Targeting one PPI of Mints is a fine-tuned approach, which can potentially avoid 
off-target effects that other proposed AD drug targets, such as the promiscuous b- and g- 




Targeting receptor complexes is emerging as an innovative approach in drug 
discovery (Rosenbaum et al., 2020). Kristian Strømgaard, our collaborator on this project, 
has already designed a successful peptide aimed to disrupt one PPI of the post-synaptic 
neuronal adaptor protein PSD-95. His lab created a PDZ domain inhibitor (AVLX-144) 
designed to disrupt the PSD-95 and NMDA receptor interaction as a treatment for 
ischemic stroke (Bach et al., 2009). Injection of the peptide into mice protected against 
ischemic brain damage (Bach et al., 2012). AVLX-144 completed Phase 1 and is 
currently moving into Phase 2 clinical trials as a treatment for ischemic stroke (Avilex 
Pharma, 2021). The success of AVLX-144 provides proof of concept that employing cell 
permeable peptides designed to disrupt PPIs is a viable therapeutic strategy. 
The recent provisional FDA approval of Aduhelm, an Ab-clearing monoclonal 
antibody, for the treatment of AD supports that Ab is viable AD therapeutic target 
(Mullard, 2021). Aduhelm aims to clear existing Ab, but combining this treatment with a 
drug aimed at preventing Ab formation could potentially strengthen the therapeutic 
effect. Currently, all the Ab-targeting drugs in Phase 3 clinical trials focus on clearing 
existing Ab (see Table 1.1), but our APPMP provides the proof-of-concept for a 
potentially efficacious drug that can reduce Ab formation. The combination of both an 
Ab preventative with an Ab clearing therapeutic has the potential to be effective in a 





CHAPTER FIVE: Molecular mechanisms underlying Mint1 autoinhibition 
(Portions of this chapter were performed by Julian Kwan, Ph.D. from Andrew Emili’s 
Lab (mass spectrometry to generate Table5.1-5.3) and Christian Bartling, Ph.D. from 
Kristian Strømgaard’s lab at the University of Copenhagen (Figure5.3). The remaining 
experiments in this chapter (neuronal experiment to generate Table5.1-5.3 and Figures 
5.1, 5,2 were performed by Shawna Henry). 
5.1 Introduction 
 The PTB domain of Mint1 is autoinhibited by an adjacent C-terminal α-helix, 
preventing APP binding. Mutating tyrosine 633 to alanine in Mint1 is able to relieve this 
autoinhibition, creating a Mint1 high affinity conformation that exhibits increased APP 
binding and Aβ production [Figure 3.2 & 3.6] (Matos et al., 2012). In this chapter, we 
will explore potential mechanisms for the relief of Mint1 autoinhibition. Typically, 
autoinhibition is relieved by either post-translational modifications (PTMs) or protein-
protein interactions (Pufall and Graves, 2002). Establishing the endogenous switch that 
relieves Mint1 autoinhibition would allow us to exploit that switch as a possible 
therapeutic target for AD.  
 Previous work has shown that Mint1 is strongly phosphorylated (Chaufty et al., 2012; 
Engholm-Keller et al., 2019; Huttlin et al., 2010; Lundby et al., 2012). Thus, to 
investigate possible Mint1 PTMs, we immunoprecipitated GFP-Mint1 from neurons 
following glutamate treatment to examine Mint1 phospho-peptide changes with mass 
spectrometry. Multiple residues were found to increase in phosphorylation following 




determine whether these phospho-residues in Mint1 are involved in Mint1 autoinhibition, 
we made sequential phospho-mimetic and phospho-resistant full length Mint1 mutants 
and performed co-immunoprecipitations from HEK cells to assay APP binding. 
Unfortunately, our phospho-mimetic and resistant Mint1 mutants did not exhibit 
alterations in APP binding. Previous work from our lab established that Mints are 
strongly phosphorylated by Src kinase, thus we interrogated Mint1-APP binding in the 
presence of constitutively active Src (c-Src). In the presence of c-Src, Mint1-APP binding 
increased when assayed using co-immunoprecipitations from HEK293T cells (Chaufty et 
al., 2012).  
 As Mint1 is a multi-domain adaptor protein that binds to several synaptic and 
Alzheimer’s related proteins, it is plausible that protein-protein interactions may be the 
mechanism of autoinhibition relief. Thus, using FP, we also assayed the affinity of the 
Mint1 mutants to a number of their known binding partners. The Mint1 high affinity 
mutant exhibited a two-fold increase in affinity for PS1 as compared to Mint1 low 
affinity, which could point to the protein-protein interaction that may relieve 
autoinhibition.   
5.2 Results  
5.2.1 Mint1 is phosphorylated following activity 
 Previous work has illustrated that synaptic activity increases the production of Ab 
in primary neurons (Cirrito et al., 2005; Kamenetz et al., 2003). Later work from our lab 
revealed that Mints specifically facilitate this activity-induced APP endocytosis and Ab 




cascade that potentially leads to Mint1 phosphorylation, relieving Mint1 autoinhibition 
and facilitating the Mint1-APP interaction. To investigate Mint1 phosphorylation changes 
following activity, we infected wild-type CD1 neurons with 20% GFP-Mint1 WT 
lentivirus on 2 DIV and stimulated neurons with 25 µM glutamate on 14 DIV. We then 
immunoprecipitated the GFP-Mint1WT from both the glutamate treated and untreated 
using a GFP antibody. Dr. Andrew Emili’s lab performed mass spectrometry on the 
isolated Mint1, identifying 20 phosphopeptides. Comparing untreated and glutamate 
treated neurons, we identified ten residues that were phosphorylated following glutamate 
treatment [Table 5.1]. Interestingly, we identified two residues that were 
dephosphorylated following activity [Table 5.2]. There were also eight consistently 
phosphorylated residues that did not change phosphorylation status with glutamate 
treatment [Table 5.3]. The majority of phosphorylation occurred on serine/threonine 
residues (80%), while tyrosine phosphorylation only accounted for 20% of all 
phosphorylated residues. The phosphorylated residues clustered around the unstructured 
N-terminal region of Mint1 [Figure 5.1A], where the sequences of Mint1, 2, and 3 are 
more divergent [Appendix Figure S2]. To ensure this N-terminal phosphorylation 
preference was not due to a bias of the peptides created during the trypsin digestion in 
preparation for the mass spectrometry, we mapped the raw peptides onto full-length 
Mint1. The peptides spanned all across Mint1, indicating the N-terminal residues are 
more prone to phosphorylation [Appendix Figure S6]. One possible explanation is that 
Mint1 uniquely contains an N-terminal Calcium/calmodulin-dependent serine protein 




because it lacked the canonical motif necessary for magnesium binding, but CASK 
adopts a constitutively active conformation that can phosphorylate substrates in a 
magnesium independent manner (Mukherjee et al., 2008). We performed an APP co-
immunoprecipitation from HEK293T cells in the presence of transfected CASK, but 
Mint1-APP interaction did not increase [Appendix Figure S7]. Thus, Mint1 
autoinhibition is most likely not relieved by CASK phosphorylation of Mint1.  
 Mint1 is a strongly phosphorylated protein, and a number of other studies have 
identified Mint1 phosphorylation in their unbiased phosphoproteomic studies. Engholm-
Keller et al., isolated synaptosomes from rat brain, depolarized them using potassium 
chloride, and performed mass spectrometry to identify phosphorylation changes 
following neuronal activation. This experiment mirrored our mass spectrometry, which 
also assayed for phosphorylation changes following neuronal activity. They identified a 
number of phosphorylated substrates, with a handful that were more phosphorylated 
following stimulation (Engholm-Keller et al., 2019). Lundby et al., created quantitative 
maps of protein phosphorylation across 14 rat organs and tissues (pancreas, brain, 
thymus, heart, kidney, perirenal fat, lung, spleen, blood, testis, muscle, stomach, 
intenstine, and liver). The Mint1 phosphopeptides identified in this study were also 
concentrated in the brain, which aligns with the neuronal specific expression profile of 
Mint1 (Lundby et al., 2012). Huttlin et al., performed phosphoproteomic characterization 
of nine mouse tissues (brain, brown fat, heart, liver, lung, kidney, pancreas, spleen, and 
testis) to create a tissue specific atlas. Their data set also classified whether these 




were either brain-biased or brain specific (Huttlin et al., 2010). We compiled the 
phosphorylation events identified by these phosphoproteomic studies to provide the 
landscape of known Mint1 phosphorylation events [Table 5.4]. This data serves to 
illustrate the extensive phosphorylation landscape of Mint1 and support that a portion of 
Mint1 phosphorylation is regulated by neuronal activity.  
5.2.2 Full-length Mint1 phosphomimetic and phosphoresistant mutants do not alter APP 
binding 
 To ascertain whether the phosphorylation events we identified following activity 
could relieve Mint1 autoinhibition, we utilized phosphomimetic amino acids that mimic 
the negative charge associated with phosphorylation. Using sequential site-directed 
mutagenesis reactions, we mutated nine of the phosphorylation changes that were 
identified in our mass spectrometry screen [Table 5.1]. Each tyrosine (Y) and threonine 
(T) were mutated to glutamate and each serine (S) was mutated to aspartate to mimic 
phosphorylation, resulting in the full-length GFP-Mint1 9X phosphomimetic (PM) 
[Figure 5.1A]. To determine whether the full length Mint1 phosphomimetic was relieved 
of autoinhibition, we performed a co-immunoprecipitation in HEK293T cells. We co-
transfected HEK293T with full-length APP and either GFP-Mint1 WT, GFP-Mint1 high 
affinity, or GFP-Mint1 9X PM and performed co-immunoprecipitation assays. [Figure 
5.1B]. As expected, GFP-Mint1 high affinity, relieved of Mint1 autoinhibition, pulled-
down more APP than GFP-Mint1 WT [Figure 5.1C]. Unfortunately, the GFP-Mint1 9X 
PM behaved similarly to Mint1 WT, binding a low basal level of APP [Figure 5.1C]. 
This suggests that the Mint1 9X PM mutant was not able to relieve the Mint1 




 We also cloned a GFP-Mint1 phosphoresistant (GFP-Mint1T306A/S314A), where 
both the residues that were identified as downregulated following glutamate treatment 
[Table 5.2] were mutated to alanine [Figure 5.1D]. We utilized this GFP-
Mint1T306A/S314A in a co-immunoprecipitation from HEK293T cells to assay APP binding. 
GFP-Mint1 high affinity was included as a control to illustrate the high-affinity APP 
binding that occurs when Mint1 PTB autoinhibition is relieved. Unfortunately, the GFP-
Mint1T306A/S314A phosphoresistant mutant bound a similar level of APP as compared to 
GFP-Mint1 WT, suggesting that the Mint1 phosphoresistant construct was still 
autoinhibited [Figure 5.1 E]. Thus, the phosphomutants informed by our mass 
spectrometry screen were unable to relieve Mint1 autoinhibition.  
5.2.3 Constitutively active Src increased Mint1-APP binding in vitro  
 Previous work from our lab and others have illustrated that Mint1 is 
phosphorylated by Src kinase in vitro (Chaufty et al., 2012; Dunning et al., 2016). Src is a 
non-receptor tyrosine kinase, and several tyrosine residues of Mint1 have been identified 
as phosphorylated in unbiased phosphopeptide mass spectrometry studies [Table 5.4]. In 
fact, one residue, Y199, which we identified as constitutively phosphorylated [Table 
5.3], lies within a canonical YEEI phosphorylation motif that Src kinase is known to 
target (Boggon and Eck, 2004). Thus, we reasoned that active Src kinase may 
phosphorylate Mint1, relieving autoinhibition and facilitating APP binding. To ascertain 
this, we transfected HEK293T cells with full-length APP, Mint1 WT, and either 
constitutively active or kinase deficient SRC. We also included Mint1 high affinity with 




relieved of autoinhibition. Mint1 WT in the presence of cSrc bound more APP than 
Mint1 WT alone. This alteration in binding was specific to the addition of active cSrc, 
because Mint1 WT transfected with kinase-deficient Src (dSrc) did not exhibit increased 
APP binding [Figure 5.2A, B]. To validate that cSrc was phosphorylating Mint1, we 
collected the cell lysate and immunoblotted for phospho-tyrosine using a 4G10 antibody. 
As expected, the cells treated with cSrc exhibited more Mint1 tyrosine phosphorylation 
than the cells with Mint1 WT alone or Mint1 WT co-transfected with dSrc [Figure 5.2 
C]. Netphos 3.1, a phosphorylation prediction algorithm, predicted a number of tyrosine 
residues may be phosphorylated in Mint1 [Figure 5.2D], supporting that Mint1 may be a 
substrate of Src kinase (Blom et al., 2004). This is supported by the phosphorylation 
studies in the literature, which identified a number of tyrosine phosphorylation events 
[Table 5.4].  
5.2.4 Binding profile of Mint1 WT, high affinity, and low affinity mutants 
 Association with another molecule is another potential mechanism that can relieve 
autoinhibition (Pufall and Graves, 2002). As Mint1 is an adaptor protein known to 
interact with a number of proteins [Figure 1.3], there is the possibility that one of these 
protein-protein-interactions could relieve autoinhibition of Mint1’s PTB domain. Our lab 
has already created a Mint1 high affinity mutant that artificially relieves the 
autoinhibition of the PTB domain, facilitating APP binding. Thus, we can leverage Mint1 
high affinity mutant and compare its binding profile with Mint1 WT, which is in the 
autoinhibited state. We also created the Mint1 low affinity mutant with two point 




3.2]. Circular dichroism did not reveal any obvious structural alterations in the Mint2 low 
affinity PTB domain, as such we do not expect the binding profile for Mint1 low affinity 
to non-APP ligands to change. To ascertain the Mint mutants’ binding profiles, we 
purified the PTB-C terminus of Mint1 WT, high affinity, and low affinity and performed 
fluorescence polarization with short ligands from known binding partners Presenilin-1 
(PS1), Neurexin, and voltage-gated calcium channels (Cav2.2) [Figure 5.3]. Interestingly, 
Mint1 high affinity exhibited a roughly 2.5-fold improved affinity (Kd = 139 ± 1.0 µM) 
for PS1 as compared to Mint1 WT (Kd = 358 ± 2.0 µM). This novel finding suggests a 
mechanism where Mint1 and PS1 binding could relieve autoinhibition of Mint1’s PTB 
domain, thereby facilitating Mint-APP binding and endocytosis while simultaneously co-
localizing the secretase (PS1) and substrate (APP) necessary to generate Ab. It is possible 
that this increase in affinity to PS1 is a result of the conformational change in the PTB 
domain when it is relieved of autoinhibition. However, more work would be necessary to 
ascertain which change is the driving force. Mint1 low affinity also exhibited a roughly 
two-fold decreased affinity (Kd = 1461 ± 25 µM) to Cav2.2 as compared to Mint1 WT (Kd 
= 619 ± 58 µM). However, these are such low-affinity interactions that this difference 










































Note: If a residue is missing the log 10 (+Glutamate/Untreated) intensity 
value, it means that position was not identified as phosphorylated in that 
trial.  
  




Acid Trial 1 Trial 2 Trial 3 
82 T 7.2  9.2 
169 Y   7.3 
239 Y 6.9 6.7  
247 S 6.9 0 -0.2 
249 S 6.8 -0.1 -0.1 
286 S   7.4 
366 T  0.4 8.5 
369 S 6.6 -0.2 0.2 
371 Y  7.1 0.1 
372 T 6.9 -0.7 0.2 




Acid Trial 1 Trial 2 Trial 3 
306 T -7.3 -6.1 0.0 
314 S -7.6 -6.9 0.2 




Acid Trial 1 Trial 2 Trial 3 
79 S   1.2 
81 S 0.1 -0.2 0.1 
84 S 0.2 -0.2 0.3 
155 S   0 
199 Y   -0.2 
243 S 0.1 -0.4 -0.2 
264 S -0.4  0.2 




Table 5.4 Mint1 phosphorylation in the literature  
Grey = residues in my Mint1 9X phosphomimetic; Blue = residues in my Mint1 
phosphoresistant; P = phosphorylated; bold P indicates activity-dependent 

























79 S P     P 
81 S P P   P 
82 T P P   P 
84 S P P   P 
155 S P     P 
169 Y P       
199 Y P    
239 Y P      P 
243 S P  P P P 
247 S P P P P 
249 S P  P P P 
264 S P   P P 
265 Y      P   
281 S   P   P 
283 S   P   P 
284 S       P 
286 S P  P P   
306 T  D P P P 
314 S D P P P 
330 T P    
366 T  P        
369 S P      P 
371 Y P      P 
372 T P    P P 
388 S   P P   
403 S       P 
405 S       P 
410 S       P 
568 S         





Figure 5.1 Mint1 phosphomimetic and phosphoresistant do not alter APP binding  
A, Schematic illustrating full length Mint1 9X phosphomimetic, including the residues 
with increased phosphorylation following glutamate treatment. Each * represents the 
approximate location of the phosphorylated residue. To create the phsosphomimetic, 
tyrosines (Y) and threonines (T) were mutated to glutamate (E) and serines were mutated 




with APP in HEK293T cells and subject to co-immunoprecipitation using a Mint1 
antibody. Representative immunoblots for Mint1 and APP from immunoprecipitation (IP, 
top), total lysate (Input, middle) and control a-tubulin (bottom). C, Quantification of 
immunoprecipitated APP was normalized to the amount of precipitated Mint1 and shown 
as percent Mint1 WT control. Data are expressed as the mean ± SEM (n = 4 independent 
experiments). The statistical significance was evaluated using one-way ANOVA with 
Sidak’s multiple comparison test, ns=no significance, ***p ≤ 0.001. D, Schematic 
illustrating full length Mint1 phophoresistant T306A/S314A, including the residues 
dephosphorylated following glutamate treatment. Each * represents the approximate 
location of the dephosphorylated residue. To create the phsosphoresistant, the residues 
were mutated to alanine (A). E, GFP-Mint1WT, high affinity, or phosphoresistant 
mutants were transfected alone or with APP in HEK293T cells and subject to co-
immunoprecipitation using a Mint1 antibody. Representative immunoblots for Mint1 and 







Figure 5.2 Active Src phosphorylates Mint1 and increases Mint1-APP binding  
A, GFP-Mint1WT was co-transfected with APP and either cSrc or dSrc in HEK293T 
cells and subject to co-immunoprecipitation using a Mint1 antibody. GFP-Mint1 high 
affinity co-transfected with APP served as a positive control. Representative 
immunoblots for Mint1 and APP from immunoprecipitation (IP, top), total lysate (Input, 
middle) as well as Src and GAPDH control (Input, bottom). B, Quantification of 
immunoprecipitated APP was normalized to the amount of precipitated Mint1 and shown 
as percent Mint1 WT control. Data are expressed as the mean ± SEM (n = 5 independent 




Sidak’s multiple comparison test, n.s. = no significance, *p ≤ 0.05, ***p ≤ 0.001.C, Input 
lysate from panel A immunoblotted with phosphotyrosine antibody, 4G10. a-tubulin 
served as a loading control (bottom). D, Rat Mint1 tyrosine residues predicted to be 
phosphorylated using NetPhos3.1 prediction software (Blom et al., 2004). Scores range 
from 0-1, with scores above 0.500 indicating positive predictions. Strongest predicted 
kinase included in the table, while unspecified represents a non-specific kinase 







  Kd mean ± SEM [µM], n=3 





PS1 DQLAFHQFYI [d] 358 ± 2.0 139 ± 1.0 301 ± 3.0 
Neurexin KKNKDKEYYV[d] 421 ± 5.3 450 ± 6.9 420 ± 0.8 
Cav2.2 LSGGRARHSYHHPDQDHWC[d] 619 ± 58 664 ± 35 1461 ± 25 
[a] maximum Mint1-PTB-C WT concentration in assay =52 µM [b] maximum Mint1-PTB-C high affinity concentration in 
assay = 32.8 μM; [c] maximum Mint1-PTB-C low concentration in assay = 44.8 μM; [d] N-terminally TAMRA-labeled 
separated with by a NNG linker 
Figure 5.3 Binding profile of Mint1 mutants  
PS1, Neurexin, and voltage-gated calcium channel (Cav2.2) peptide affinity for the 
mutant Mint1 PTB to C-terminus constructs (included PPI domains depicted above the 
table) as determined by FP. (n = 1 independent experiment with 3 biological replicates).  
 
  





 In an effort determine the mechanism that relieves the autoinhibition of Mint1’s 
PTB domain, we examined both PTMs as well as protein-protein interactions. Our lab 
has shown that Mints are required for activity-induced APP endocytosis and 
amyloidogenic processing. Thus, we hypothesize that neural activity could activate a 
kinase that would phosphorylate Mint1, facilitating the Mint-APP interaction (Sullivan et 
al., 2014). We therefore performed phosphopeptide mass spectrometry on GFP-Mint1 
WT immunoprecipitated from stimulated and unstimulated neurons. We identified ten 
residues that were phosphorylated following activity [Table 5.1], two residues that were 
dephosphorylated following activity [Table 5.2], and eight residues that were 
constitutively phosphorylated [Table 5.3]. Our phosphorylation study was further 
supported and expanded upon by a number of unbiased mass spectrometry studies [Table 
5.4]. In fact, mass spectrometry performed following stimulation of isolated rat brain 
synaptosomes identified a number residues that were phosphorylated following activity, 
corroborating some residues identified in our screen (Engholm-Keller et al., 2019).  
 To ascertain whether phosphorylation of the residues we identified would relieve 
autoinhibition and increase APP affinity, we cloned a GFP-Mint1 9X phosphomimetic 
(PM) where each tyrosine (Y) and threonine (T) were mutated to glutamate (E) and each 
serine (S) was mutated to aspartate (D) [Figure 5.1A]. Unfortunately, in a co-
immunoprecipitation assay from HEK293T cells this GFP-Mint1 9X phosphomimetic 
mutant did not increase APP binding as compared to GFP-Mint1 WT [Figure 5.1B, C]. 




mutating T306 and S314 to alanine and performing co-immunoprecipitations with APP 
from HEK293T cells. This GFP-Mint1 phosphoresistant mutant also did not alter APP 
binding compared to GFP-Mint1 WT, suggesting the phosphorylation state of these 
particular residues does not affect the autoinhibition of the PTB domain [Figure 5.1D, 
E].  
 Although our phosphomimetic and phosphoresistant Mint1 mutants did not alter 
APP binding in vitro, this does not rule out that phosphorylation could be the mechanism 
that relieves autoinhibition. First, phosphomimetic amino acids are not the perfect tool to 
recapitulate phosphorylation, as they are smaller and only exhibit one negative charge 
unlike the two found in phosphate functional groups (Chen and Cole, 2015). Further, as 
illustrated in Table 5.4, there are a number of phosphorylations that were not pulled out 
in our screen but were shown as phosphorylated in other screens. Mint1 is such a strongly 
phosphorylated substrate that it is possible that our mimetic construct lacked the 
necessary residue that relieved Mint1 autoinhibition. In theory, it could be a combination 
of phosphorylated residues that relieve Mint1 autoinhibition, and our phosphomimetic 
mutant did not have the correct combination.  
 As there are so many potential residues that can be phosphorylated in Mint, we 
pivoted from interrogating residues within Mint1 to investigating the effect of kinases 
that are known to phosphorylate Mint1. Previous in vitro work revealed that Src kinase 
phosphorylates Mint1 and 2, altering the trafficking of APP (Chaufty et al., 2012; 




intracellular Ab accumulation, suggesting that in the presence of cSrc Mint and APP may 
interact more, facilitating Ab production (Chaufty et al., 2012).  
 To interrogate whether Src phosphorylation of Mint1 would increase Mint1-APP 
binding, we transfected GFP-Mint1WT and APP in the presence of cSrc or kinase-
deficient Src (dSrc) and then immunoprecipitated Mint1. Mint1 co-transfected with cSrc 
interacted with significantly more APP compared to Mint1 WT alone. This increase in 
Mint1-APP interaction was lost in the presence of dSrc, indicating this alteration in APP 
affinity was phosphorylation specific [Figure 5.2A, B]. It is worth noting that there 
seems to be a slight increase in APP binding in the presence of dSrc, but this could be 
attributed to a low level of phosphorylative activity that may still be occurring with this 
kinase-deficient point mutant. It is important to consider that c-Src could exert off-target 
affects that may indirectly alter Mint1-APP binding; therefore, it will be important to 
identify the tyrosine residues that are phosphorylated via Src. If the residues are 
identified, creating phosphorylation resistant mutants would allow us to interrogate the 
effects specific to Mint1 phosphorylation.  
 Netphos 3.1, an algorithm that predicts phosphorylated residues, identified 13 
tyrosines that could be phosphorylated in Mint1 [Figure 5.2D] (Blom et al., 2004). For 
most of the residues, the algorithm was unable to predict a specific kinase, so it is 
possible they could be targets of Src kinase. In fact, NetPhos 3.1 predicted 
phosphorylation of residue Y199, which lies within a canonical YEEI phosphorylation 
motif that Src kinase is known to target (Boggon and Eck, 2004). In vitro studies in COS 




terminal Mint1 tyrosine phosphorylation. The Y199 residue was also shown to be 
phosphorylated in cultured neurons, and this phosphorylation was prevented using the Src 
kinase family inhibitor PP2. An unphosphorylatable Y199F mutant altered neuronal 
trafficking of APP, suggesting that this residue is important in the Mint1-APP cellular 
dynamics (Dunning et al., 2016). One trial of our mass spectrometry screen also 
identified Y199 as phosphorylated [Table 5.3], but it was not upregulated following 
activity. For this reason, this residue was not included in my Mint1 9X phosphomimetic 
mutant; it may be possible that phosphorylation of this Y199 residue is key for relieving 
autoinhibition.  
 Previous work from our lab established that mutation of Y633 to both alanine (to 
remove the aromatic side chain) and glutamate (to mimic the negative charge of 
phosphorylation) relieved autoinhibition and increased APP binding (Matos et al., 2012). 
Thus, it is reasonable to hypothesize that phosphorylation of that residue could 
potentially be the switch to relieve autoinhibition. However, phosphopeptide analysis 
from our lab and the others in literature did not identify this residue as phosphorylated, so 
it is most likely not phosphorylated in vitro. According to the Mint1 PTB domain crystal 
structure, it appears Y633 is most likely sterically hindered from kinase accessibility 
(Matos et al., 2012).  
 The C-terminal autoinhibitory helix that occludes the APP binding pocket of the 
PTB domain is conserved in Mint1 and 2, but the sequence is divergent in ubiquitously 
expressed Mint3 [Appendix Figure S2]. This suggests that PTB domain autoinhibition is 




autoinhibition in Mint2 have been determined, but they are more extensive than the single 
point mutation (Y633) that relieves Mint1 inhibition (Matos et al., 2012; Xie et al., 2012). 
To see if this single point mutation would also relieve autoinhibition of Mint2’s PTB 
domain, I introduced the analogous Y633A point mutation onto Mint2 (Y544A) 
[Appendix Figure S8]. However, I did not observe any alterations in Mint2Y544A-APP 
affinity, which suggests that the mechanisms to relieve autoinhibition may differ between 
Mint1 and 2, which is not surprising considering their preferential expression in different 
subsets of neurons.  
 Intermolecular protein-protein interactions are another mechanism that can 
potentially relieve autoinhibition. A number of proteins that interact with Mint1 are 
known; therefore, we examined whether the Mint1 mutants exhibit unique binding 
profiles. Using purified PTB to C-terminus Mint1 WT, high affinity, and low affinity 
constructs, we performed FP to determine binding affinity to PS1, Neurexin, and Cav2.2 
[Figure 5.3]. Interestingly, Mint1 high affinity had a 2.5-fold increased affinity for PS1. 
Work from our collaborators suggests that PS1 prefers to bind the first PDZ domain of 
Mint2, adjacent to the PTB domain (Jensen et al., 2018). This suggests that PS1 binding 
could potentially alter the conformation of the autoinhibitory a-helix, relieving 
autoinhibition of the PTB domain. More work would be necessary to examine whether 
PS1 binding initiates the relief of autoinhibition or if once autoinhibition is already 
relieved PS1 then binds with higher affinity. To investigate whether this change in 




Figure S9]. Preliminary results suggest that Mint1 high affinity, which binds PS1 with 
greater affinity, does indeed cleave APP CTFs more efficiently.  
 Regulation of adaptors and scaffolding proteins by intramolecular interactions and 
conformational reorganization is a common mechanism (Feng and Zhang, 2009). In fact, 
the C-terminal tail of Mints has also been shown to fold back and autoinhibit the PDZ 
domains of Mints, meaning that not only the PTB but also the PDZ domains of Mint1 are 
autoinhibited. This PDZ domain autoinhibition is regulated by a tyrosine residue, where 
mutation of the residue to glutamate abolished the C-terminal tail mediated autoinhibition 
(Long et al., 2005). Thus, there is strong evidence that tyrosine phosphorylation, possibly 
mediated by Src kinase, can relieve Mint1 PTB domain autoinhibition and increase APP-
Mint1 interaction. Future studies will aim to examine the underlying mechanism 





CHAPTER SIX: Discussion and future directions 
6.1 Major findings  
 The goal of this work was to characterize the APP-Mint1 interaction, which is 
involved in the amyloidogenic processing pathway associated with AD. Mints bind to the 
endocytic YENPTY motif located in the C-terminus of APP, facilitating APP endocytosis 
and Ab production (Borg et al., 1996; Sullivan et al., 2014). After extensive biochemical 
characterization of the Mint PTB domain that mediates APP-Mint binding, we generated 
Mint1 mutants that bind with high affinity (Mint1Y633A) or low affinity (Mint1Y549A/F610A) 
to APP. Immunocytochemistry of the high and low affinity Mint1 mutants in primary 
mouse neurons revealed that Mint1 binding to APP is essential for Mint1’s Golgi and 
pre-synaptic localization [Figure 3.3 & 3.4]. We also characterized the amyloidogenic 
APP processing pathway in primary mouse neurons infected with the Mint1 mutants. Not 
only did Mint1 low affinity decrease Mint1-APP colocalization, but it also reduced APP 
endocytosis and lowered Ab release in primary neurons [Figure 3.5 & 3.6]. 
 We also generated a cell-permeable APP mimetic peptide that interferes with the 
APP-Mint interaction. This high affinity APP mimetic peptide (APPMP) was designed to 
outcompete endogenous APP binding. Quantitative fluorescent polarization revealed that 
APPMP exhibited a 46-fold improved affinity to Mint2 as compared to APPWT [Figure 
4.2]. Initial in vitro characterization of the APPMP using plasma stability and hepatocytic 
clearance assay revealed APPMP is proteolytically stable [Figure 4.3]. Conjugation of the 
cell-permeating TAT tag to APPMP facilitated the peptide’s entry into primary neurons 




variants of the APPMP   reduced Ab42 production with minimal toxicity [Figure 4.4 and 
4.5].  
The Mint1 PTB domain that mediates APP binding is typically autoinhibited by a 
C-terminal autoinhibitory helix (Matos et al., 2012). Since post-translational modification 
is one mechanism for alleviating protein autoinhibition, and Mint1 is highly regulated by 
phosphorylation, we performed mass spectrometry and identified several Mint1 phospho-
sites [Table 5.1-5.3]. In addition, we found constitutively-active Src kinase, a kinase 
implicated in Mint phosphorylation, enhanced APP-Mint1 binding [Figure 5.2]. As 
Mint1 is a multi-domain adaptor protein that binds to several synaptic and Alzheimer’s 
related proteins, it is plausible that protein-protein interactions may be the mechanism of 
autoinhibition relief. As such, we characterized the binding profile of the Mint1 WT, high 
affinity, and low affinity mutants, revealing that Mint1 high affinity has a 2.5-fold 
improvement in affinity for PS1 as compared to Mint1 WT [Figure 5.3]. These results 
shed light into the mechanism that may relieve Mint1 autoinhibition, which is another 
potential point of intervention that can be targeted to prevent Mint-mediated 
amyloidogenic APP processing. Taken together, this work supports that Mints typically 
facilitate APP endocytosis and Ab production and supports that targeting the APP-Mint 
interaction is a viable strategy to ameliorate AD-associated Ab production.  
6.2 Mint’s role at the Golgi 
Work in Drosophila showed that Mints function at the Golgi to control polarized 
trafficking of axonal membrane proteins, such as APP. It was hypothesized that Mints 




axon (Gross et al., 2013). In fact, Mints have been shown to bind to ADP ribosylation 
factor (Arfs), which function at the Golgi to facilitate the sorting of membrane proteins 
for transport (Hill et al., 2003). Further, work in HELA cells revealed that recruitment of 
Mint3 is necessary for export of APP from the Golgi (Caster and Kahn, 2013). Thus, 
although we typically consider Mints as mediating the endocytosis of APP from the 
plasma membrane, there is evidence that they may also act at the Golgi to bud and 
package APP-containing vesicles for transport. Considering this, our Mint1 low affinity 
mutant, which did not localize to the Golgi, could perturb trafficking of APP from the 
Golgi.  
To investigate Mint’s role at the Golgi, we could utilize the huAPP695-RFP 
exon7 mutant we cloned [Appendix Figure S5] to live cell image APP dynamics at the 
Golgi in primary neurons. Similar to our investigation with the cell surface protein, 
Neurexin, at the Golgi with Mint2 (Lin et al., 2019), we could perform fluorescence 
recovery after photobleaching (FRAP) at the Golgi and quantify the amount of immobile 
APP in Mint knockouts compared to endogenous neurons carrying Mints (or in the 
presence of Mint1 low affinity and high affinity mutants).  
6.3 Mint’s role in endocytosis 
 Mint1 has been shown to specifically alter APP endocytosis (Sullivan et al., 
2014), and APP endocytosis is known to occur via clathrin coated pits (Koo and Squazzo, 
1994). However, we have never explored the role that Mints play in clathrin-mediated 
endocytosis. Early in endocytosis, high levels of negatively charged phosphatidylinositol 




Typically, a clathrin adaptor protein (AP) complex, will target to the membrane, binding 
to both clathrin triskeletons and the target transmembrane cargo protein, coupling cargo 
recruitment with clathrin coat polymerization (Beacham et al., 2019). AP2, the clathrin 
adaptor that mediates trafficking from the plasma membrane to endosomes, contains a 
string of positively charged amino acids in its sequence which targets it to negatively 
charged PIP2 microdomains (Beacham et al., 2019).  
We hypothesized that Mint may act as a clathrin adaptor protein, binding both 
clathrin and APP at the membrane and participating the assembly of the clathrin coated 
vesicle. Interestingly, just like Mints, APs undergo conformational switches between 
active and inactive states, and this switch is controlled via reversible phosphorylation 
(Wrobel et al., 2020). Even though previous work suggested that Mints may bind to 
clathrin (Hill et al., 2003), we were unable to validate this finding [Appendix Figure 
S10]. However, early work illustrated that the Mint1 PTB domain can bind to PIP2 
(Okamoto and Sudhof, 1997). Using PIP2 beads incubated with HEK293T cell lysate 
transfected with a GFP-Mint1 PTB domain construct, we were able to confirm that the 
Mint1 PTB domain does indeed bind to PIP2 [Appendix Figure S10].  
We identified a string of positive amino acids [KSRKK position 503-507] that lies 
within an unstructured surface region of Mint1’s PTB domain [see Figure 1.4]. Thus, we 
hypothesized that these positive amino acids may facilitate Mint1 binding to PIP2 while 
simultaneously interacting with APP. This mechanism would be similar to that of Dab1, 
another PTB-domain containing neuronal adaptor protein, that simultaneously binds to 




al., 2003). Using dbPTM, a database that curates experimentally validated post-
translational modifications, we found that the lysine residues (K500, K503, and K507) in 
that positive string of amino acids were confirmed to be acetylated by mass spectrometry 
analysis (Bouchut et al., 2015; Huang et al., 2018). Acetylation of lysines, which 
neutralizes their positive charge, regulates PIP2 binding, acting as an on/off membrane 
switch (Song et al., 2019). Thus, we proposed that acetylation of K500, K503, and K507 
could regulate Mint1’s binding to PIP2. To test this, we mutated the K500, K503, and 
K507 as well lysine K506 to either arginine (R), an acetylation resistant mimetic, or 
glutamine (Q) to mimic acetylation. We then transfected cells with GFP-Mint1 PTB WT, 
GFP-Mint1 PTB acetylation mimetic, or GFP-Mint1 PTB acetylation resistant and 
performed a pull down using PIP2 beads. Preliminary results indicate that lysine 
acetylation did not alter PIP2 interaction [Appendix Figure S10].  
The aforementioned string of positively charged amino acids is located within 
Mint1 exon 6, which is a short 11 amino acid exon. A Genotype-Tissue Expression 
(GTEx) database search revealed that exon 6 of Mint1 is highly conserved in the brain, 
with exon junction analysis revealing that exon 6 is rarely spliced out. Alignment of 
Mint1, 2, and 3 [Appendix Figure S2] revealed that while Mint1 and 2 contain the 
conserved positive amino acid PIP2 binding motif, it was not conserved in Mint3. This 
suggests that PIP2 binding may be a brain-specific function for Mints1 and 2 and not for 
the ubiquitously expressed Mint 3 protein. Recent alternative splicing studies of human 
AD brains revealed that Mint1 exon 6 is downregulated in AD brains compared to 




physiologically relevant splice event that could be a disease-related switch that alters 
Mint1’s function. Thus, we were interested to examine whether the Mint1 PTB domain 
lacking exon 6 would exhibit altered PIP2 affinity. We cloned a Mint1 PTB domain 
lacking exon 6 (GFP-Mint1 PTB Dexon 6) and performed a pull-down using PIP2 beads. 
Preliminary results suggest that this PTB domain lacking exon 6 did not exhibit any 
changes in PIP2 binding as compared to the WT Mint1 PTB domain [Appendix Figure 
S10].  
These preliminary experiments suggest that Mint1 and PIP2 do interact, which 
could potentially mediate Mint’s role in endocytosis. PIP2 is also implicated in vesicle 
exocytosis (Koch and Holt, 2012), which Mint proteins have already been shown to 
regulate (Ho et al., 2006), so the interaction with PIP2 may support Mint’s role in 
exocytosis. Future experiments to explore the importance of Mint1-PIP2 interaction could 
include treating neurons with neomycin (to shield negatively charged PIP2 at the 
membrane) or treating neurons with phospholipase C (PLC) (the enzyme that metabolizes 
PIP2) and assaying for Mint’s localization as well as endocytic activity. We could also 
investigate whether targeting Mint1 to the PIP2 rich membrane would increase vesicle 
endocytosis or exocytosis. We could accomplish this via cloning a pleckstrin homology 
domain, which has high affinity binding to PIP2, to the N-terminus of Mint1 (Koch and 
Holt, 2012).  
We did not see alterations in PIP2 affinity with the acetylation mutants or Dexon 6 
mutant, indicating another positively charged amino acid may mediate PIP2 binding. In 




Therefore, it is likely that we may have missed an essential amino acid. However, lysines 
are also potential sites of ubiquitinylation. Thus, these lysines in exon 6 could be 
implicated in the proteasomal degradation of Mint1. To investigate this possibility, we 
could perform an ubiquitinylation assay using the Mint1 WT and Mint1 Dexon 6 
constructs. We would treat HEK293T cells with the proteasomal inhibitor MG132 to 
accumulate ubiquitinylated proteins, immunoprecipitate Mint1 and immunoblot for 
ubiquitin. If the lysines within exon 6 are important for ubiquitinylation, we would see 
decreased ubiquintylation of the Mint1 D exon 6 construct. If the lysines in exon 6 are 
indeed sites for ubiquitin, it would suggest that Mint1 D exon 6 would be more stable. 
Interestingly, exon 6 is downregulated in AD brains, and Mint1 protein level was 
upregulated in AD brains, supporting this as a possible mechanism (Jacobs et al., 2006).  
6.4 Therapeutic peptide  
 We illustrated that 24 h treatment of primary AD mouse neurons with the cell-
permeable APPMP reduced Ab42 production with minimal toxicity (Bartling et al., 2021). 
Our collaborator has since optimized the peptide, producing a second-generation APPMP 
with improved solubility, cell permeability and cytotoxicity. There are a number of 
mechanistic questions that have yet to be answered about our APPMP.  
To investigate which Mint isoforms the peptide binds, we can conjugate the 2nd 
generation APPMP to beads and perform a pull-down from neuronal lysate (similar to 
Figure 4.2D). As the PTB domain of Mints1-3 is highly conserved, it will most likely 
interact with all three isoforms, but that has yet to be determined. Using the same pull-




target proteins the 2nd generation APPMP interacts with. A number of adaptor proteins 
interact with APP’s YENPTY motif, such as Dab1, Fe65, Shc, JIP-1, Numb, and Grb2, 
so the peptide could potentially interact with some of these proteins (Russo et al., 2005). 
Our collaborators could also perform FP with purified Mint1, 2, and 3 proteins to 
quantitatively measure the affinity of the second-generation APPMP for each Mint 
isoform.  
Using primary neurons, we could begin to terse apart the mechanisms by which 
the APPMP reduces Ab production. We could treat primary neurons with riTAT-2nd 
generation APPMP or a control peptide and perform an APP endocytosis assay. This 
endocytosis assay would illuminate whether the riTAT-2nd generation APPMP is reducing 
APP endocytosis. We could also co-stain for PS1, to determine whether the riTAT-2nd 
generation APPMP reduces the co-localization of APP and PS1. To interrogate if the 
processing of APP is altered following peptide treatment, we could immunoblot for 
soluble APPa and b in the neuronal supernatant, to quantitate whether there are any 
changes in a- or b- secretase cleavage. In addition, we could perform the g-secretase 
activity assay [similar to Appendix Figure S9] to determine whether PS1 activity on 
APP is altered. My work has shown that the Mint1 low affinity mutant, which does not 
interact with APP, mislocalizes away from the Golgi and pre-synaptic compartment 
[Figure 3.3 & 3.4]. Thus, it is important to ensure that introducing the APPMP, which 
disrupts the APP-Mint1 interaction, does not alter Mint’s localization. To accomplish 
this, we can immunostain for endogenous Mints in neurons treated with the peptide. We 




their appropriate subcellular compartment and this localization will not be perturbed with 
peptide treatment. Electrophysiological analysis of peptide-treated neurons would also 
illuminate whether the peptide perturbs Mint’s pre-synaptic vesicle release functions. We 
could use FM 1-43 dye to investigate the synaptic vesicle exocytosis and endocytosis in 
neurons treated with the peptide (Gaffield and Betz, 2006).  
As the APPMP was successful in vitro at reducing Ab production, the next step 
will be to begin in vivo testing using aged APPswe/PS1DE9 transgenic mice. First, we 
would inject mice either intraperitoneally (I.P.) or intravenously (I.V.) with a dose curve 
of riTAT-2nd generation APPMP and euthanize the mice 24 h later. We would perform 
mass spectrometry on the plasma and brain tissue to get an idea of the pharmacokinetics 
of the peptide. With this, we could calculate a brain/plasma ratio to generate a dose curve 
that will inform the optimal concentrations for treatment moving forward. Once we have 
a general idea of preferred injection route and effective peptide doses, we can determine 
the effect of the peptide on Ab levels. We could inject four-month-old AD mice once a 
day for a week with peptide and then collect one half of the brain for Ab 
immunohistochemistry and the other half for an Ab40/42 ELISA. The age of the treated 
mice as well as the time course of collection suggested above were informed by an in 
vivo study of a g-secretase inhibitor (Best et al., 2007). In addition, we could conjugate 
the peptide to a small fluorophore such as FITC which would allow us to simultaneously 





Pending the success of acute dosing of the peptide, we could perform chronic 
dosing over time, to establish the peptide’s effectiveness on a larger time scale (e.g. 
months). With chronic treatment, we would be able to investigate cognitive deficits in the 
mice to determine whether the AD mice are rescued with peptide treatment. We could 
perform assays such as contextual fear-conditioning to interrogate contextual memory 
(Janus et al., 2015) and cued-target Barnes maze to test working memory (O’Leary and 
Brown, 2009). Chronic treatment also facilitates investigating systemic changes in the 
brain. To examine for gliosis and cell death in treated mice, we could immunostain the 
brain slices using antibodies to GFAP (astrocytes), Iba1 (microglia), and FluoroJade C 
which labels degenerating neurons (Porchet et al., 2003; Schmued et al., 2005).  
6.5 Mint1 autoinhibition  
 This work illustrated that Src phosphorylation of Mint1 relieves autoinhibition, 
increasing APP-Mint1 binding [Figure 5.2]. However, this was only illustrated in 
HEK293T cells, and it will be necessary to explore the APP-Mint1 interaction in the 
neuronal context. Our lab previously identified three Src-phosphorylated tyrosine 
residues in the N-terminus of Mint2 that altered APP trafficking in primary neurons. In 
fact, AD primary mouse neurons infected with cSrc increased APP internalization and 
intracellular Ab (Chaufty et al., 2012). However, it was not confirmed that these were 
Mint-mediated effects. Now, we could utilize our Mint1 low affinity mutant, which does 
not interact with APP, to terse this apart. We could knock out endogenous Mints in MFT 
neurons and rescue with either GFP-Mint1 WT or Mint1 low affinity co-infected with 




immunocytochemistry. If cSrc is altering APP dynamics through a Mint-mediated 
mechanism (e.g relieving autoinhibition), then the Mint1 WT infected neurons would 
exhibit increased APP endocytosis and intracellular Ab when co-infected with cSrc while 
the neurons infected with Mint1 low affinity, which does not bind Mint1, would not show 
any differences in APP internalization or Ab accumulation.   
 It is also important to identify which residues Src is phosphorylating, because this 
would allow us to create an artificial phosphomimetic and further study the trafficking 
dynamics of Src-phosphorylated Mint1. To accomplish this, we could perform an in vitro 
phosphorylation assay, incubating Mint1 alone or with cSrc and performing 
phosphopeptide analysis. By comparing the two phosphorylation profiles, we could 
identify which tyrosine residues are phosphorylated by Src. Then, we could create a 
phosphomimetic (glutamate) or phosphoresistant (phenylalanine mutant) and use this to 
perform immunocytochemistry (or potentially live imaging) to visualize if Mint1 or APP 
are trafficking differently.  
 Previous unpublished work from our lab illustrated that Mints and APP localize to 
lipid rafts in primary neurons. Neuronal Src, which is myristoylated, is recruited to lipid 
rafts in the brain where it is turn more catalytically active (Mukherjee et al., 2003). Thus, 
we hypothesized that once Mint1 is targeted to the lipid rafts at the membrane (possibly 
by PIP2 binding), it can then be phosphorylated by the membrane bound Src. This 
phosphorylation can relieve the autoinhibition of the Mint1 PTB domain, facilitating the 
Mint1-APP interaction and subsequent endocytosis [Figure 6.1]. Once again drawing 




kinases (Bock and Herz, 2003), and this phosphorylation is dependent on interaction with 
PIP2 (Huang et al., 2005). Thus, it would be interesting to investigate whether preventing 
Mint1 membrane association would alter the tyrosine phosphorylation state of Mint1. We 
could accomplish this by infecting GFP-Mint1 into primary neurons and then activating 
PLC to deplete PIP2 in the membrane. We could then immunoprecipitate GFP-Mint1 and 
immunoblot with 4G10 to assay tyrosine phosphorylation.  
 The FP data characterizing the binding profile of the Mint1 APP binding mutants 
revealed that PS1 has a greater binding affinity to GFP-Mint1 high affinity [Figure 5.3]. 
We could start to interrogate this in vitro by infecting neurons with Mint1 WT and high 
affinity and then staining for PS1 colocalization. We would expect that Mint1 high 
affinity may exhibit a higher degree of co-localization with PS1. To test whether PS1 
binding initiates the relief Mint1 autoinhibition or is a consequence of relief, we could 
introduce either full length PS1 or a cell-permeable PS1 C-terminal peptide [Figure 5.3] 
onto HEK293T cells transfected with Mint1 WT and APP and assay whether APP 
binding was increased. We could also potentially investigate this in neurons, knocking 
down PS1 and performing an APP endocytosis assay. If PS1 is necessary to relieve Mint1 
autoinhibition, we would observe a decrease in APP internalization as compared to the 
neurons with PS1. 
  This increased affinity between PS1 and the un-autoinhibited Mint1 may provide 
a unique therapeutic opportunity. We could create a dimer therapeutic peptide with both 
the APPMP and a high affinity PS1 peptide attached with a linker. Thus, the dimer peptide 




enough in Mint’s tertiary structure). This dimer peptide, targeting two PPI domains of 
Mint1, would immensely increase the peptide’s specificity. This would be a similar 
paradigm to the tandem PDZ domain inhibitor for PSD-95 that our collaborators 
currently have in Phase 2 clinical trials (Bach et al., 2012).   
6.6 Conclusion 
 AD has been studied for over a century, but the exact mechanisms of the disease 
are still disputed. As such, the majority of therapeutic strategies have failed in a clinical 
trial setting. Recently, the first disease-modifying treatment for AD, Aduhelm, an Ab 
clearing monoclonal antibody, was provisionally FDA approved (Mullard, 2021). This 
provisional approval was controversial, and results from the impending confirmatory trial 
will reveal whether the drug is efficacious in a larger patient cohort. If this treatment 
doesn’t succeed, the prevalence of AD is expected to rise over two-fold by 2050. With 
this predicted surge in cases, AD associated medical costs are expected to reach $1.1 
trillion by 2050 (Alzheimer’s Association, 2021). Thus, there is an immense demand to 
identify novel therapeutic targets for the treatment of AD. This work biochemically 
characterized the Mint-APP interaction and how it affects amyloidogenic processing, 
provided a proof of concept for targeting the APP-Mint1 interaction as an AD therapeutic 
target, and suggested a novel mechanism for the relief of Mint1 autoinhibition. Together, 
this work constructs a foundation for targeting the APP-Mint interactions as an AD 










Top, PIP2 concentrates in a portion of the plasma membrane preparing for endocytosis. 
Mint1 is then targeted to the endocytic plasma membrane via PIP2 binding. At the plasma 
membrane, Mint1 is localized to myristoylated Src, which then phosphorylates Mint1’s 
N- terminus. Middle, Src-phophorylated-Mint1 is relieved of PTB domain autoinhibition. 
Mint1 can now bind APP and initiate APP endocytosis. Mint1 bound to APP 
simultaneously binds to PS1, the catalytic core of the g-secretase complex. Bottom, APP 
and PS1 are trafficked into an endosome via Mint1. Within the acidic endosome, 
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are boxed in red. * indicates a fully conserved residue. : indicates 
conservation between groups of strongly similar properties. . indicates conservation 











Residues mutated to create low affinity Mint1Y549A,F610A and low affinity Mint2Y460A,F521A 
boxed in red. Point mutation to create high affinity Mint1Y633A boxed in green. 
Autoinhibitory sequence C-terminal to PTB domain labeled and boxed in blue. Exon 6, 
labeled and boxed in black, is conserved in Mint1 and 2 but missing in Mint3. * indicates 
a fully conserved residue. : indicates conservation between groups of strongly similar 
properties. . indicates conservation between groups of weakly similar properties.  







Figure S3 Mint1 mutants alter APLP1 and APLP2 binding in vitro 
A, GFP-Mint1WT, high affinity, or low affinity mutants were co-transfected with APLP1 
in HEK293T cells and subject to co-immunoprecipitation using a Mint1 antibody. 
Representative immunoblots for Mint1 and APLP1 from immunoprecipitation (IP, top), 




immunoprecipitated APLP1 was normalized to the amount of precipitated Mint1 and 
shown as percent Mint1 WT control. Data are expressed as the mean ± SEM (n = 5 
independent experiments). The statistical significance was evaluated using one-way 
ANOVA with Sidak’s multiple comparison test, *p < 0.0.05. C, GFP-Mint1WT, high 
affinity, or low affinity mutants were co-transfected with APLP2 in HEK293T cells and 
subject to co-immunoprecipitation using a Mint1 antibody. Representative immunoblots 
for Mint1 and APLP2 from immunoprecipitation (IP, top), total lysate (Input, middle) 
and control a-Tubulin (bottom). D, The amount of immunoprecipitated APLP2 was 
normalized to the amount of precipitated Mint1 and shown as percent Mint1 WT control. 
Data are expressed as the mean ± SEM (n = 4 independent experiments). No statistical 






Figure S4 Mint1 mutants alter spontaneous synaptic release  
A, Sample traces showing miniature excitatory postsynaptic currents (mEPSCs) from 




mutants at 14-17 DIV.B, Bar graphs of the quantification revealed a significant increase 
in both frequency and amplitude in neurons rescued with GFP-Mint1 high affinity 
mutant. Data are expressed as the mean ± SEM (n = 1 independent experiment, number 
of individual cells in the bottom of each bar). The statistical significance was evaluated 
using one-way ANOVA with Sidak’s multiple comparison test, * p ≤ 0.05, **p ≤ 0.01, 
and ***p ≤ 0.001. C, Western blot illustrating postsynaptic (PSD-95) and presynaptic 
(Synapsin) protein expression in neurons treated with the same lentivirus paradigm used 
in the electrophysiology experiment. PSD-95 and Synapsin expression levels are the 
same in all three Mint1 mutant treatment groups, suggesting the number of synapses has 







Figure S5 Basic characterization of huAPP 695-RFP exon 7  
A, Top: Schematic representation of human APP 695, the neuronal specific isoform 
lacking exons 7 and 8, with each exon labeled, adapted from (Dawkins and Small, 2014). 




exon 6. B, huAPP695, huAPP695-RFP exon 7, or huAPP695-GFP were transfected alone 
or with GFP-Mint1 WT in HEK293T cells and subject to co-immunoprecipitation using a 
Mint1 antibody. Representative immunoblots for Mint1 and tagged APP from 
immunoprecipitation (IP, top), total lysate (Input, middle and bottom). Untagged 
huAPP695 and our novel huAPP695-RFP exon 7 interacted with Mint1, while the C-
terminally tagged huAPP695-GFP did not interact with Mint1, most likely due to the 
large fluorescent tag sterically preventing Mint interaction. C, Primary MFA neurons 
were infected with GFP-Mint1 high affinity at 2 DIV. Neurons were fixed at 10 DIV, 
immunolabeled with GFP (Mint1) then mounted for fluorescence analysis. 
Representative image shows GFP-Mint1 (green) and huAPP695-RFP exon 7 (red). (n = 1 






Figure S6 Raw peptides from all three trials of mass spectrometry 
Mint1 (white) and its protein-protein interaction domains (labeled) along with the raw 
peptides (black bars) isolated in our mass spectrometry analysis. The peptides span the 
length of Mint1, indicating the N-terminal phosphorylation bias is not an artifact of poor 






Figure S7 CASK does not increase APP-Mint1 binding in vitro 
A, GFP-Mint1 WT and GFP-Mint1 high affinity were transfected with APP alone or with 
both APP and CASK in HEK293T cells. Cells were then subject to co-
immunoprecipitation using a Mint1 antibody. Representative immunoblots for Mint1, 
APP, and CASK from immunoprecipitation (IP, top three blots) and total lysate (INPUT, 
blots 4-6) along with a-Tubulin as a loading control (INPUT, bottom blot). B, The 
amount of immunoprecipitated APP was normalized to the amount of precipitated Mint1 
and shown as percent Mint1 WT control. Data are expressed as the mean ± SEM (n = 2 
independent experiments, 4 biological replicates). The statistical significance was 
evaluated using one-way ANOVA with Sidak’s multiple comparison test, ns=no 






Figure S8 Mint2Y544A does not alter APP binding in vitro  
A, GFP-Mint2WT or GFP-Mint2Y544A were co-transfected with APP in HEK293T cells and 
subject to co-immunoprecipitation using a GFP antibody. Representative immunoblots 
for Mint2 and APP from immunoprecipitation (IP, top), total lysate (Input, middle) and 
control GAPDH (bottom). B, The amount of immunoprecipitated APP was normalized to 
the amount of precipitated Mint2 and shown as percent Mint2 WT. Data are expressed as 
the mean ± SEM (n = 2 independent experiments). No significance was found using an 










A-B, Representative immunoblot of cultured MFTtg neurons infected with Cre to 
knockout Mints and rescued with GFP-Mint1 high affinity (A) or GFP-Mint1 low affinity 
(B). Neurons were pretreated with control (DMSO) or 2 µM DAPT for 24 h on 15 DIV to 
cause the accumulation of APP-CTFs. DAPT was then washed out and replaced with 
conditioned neuronal growth media for the duration of the experiment in which lysates 
were collected at 0, 4, 12, and 24 h after DAPT washout. C83 fragment produced by a-
secretase cleavage while the C89 and C99 fragments are produced by b-secretase 
cleavage. C83 and C89 bands are difficult to resolve, so we can only separately quantify 
the C99 and the combined C83 and C89 CTFs. GAPDH served as a loading control 
(bottom). C-D, APP-CTF levels first normalized to GAPDH and then to time 0 (the 
highest point of CTF accumulation) to compare the speed at which g-secretase cleaves the 
CTFs after DAPT washout. In panel C, neurons infected with GFP-Mint1 high affinity 
cleaved the C83 and C89 APP CTFs faster than neurons infected with GFP-Mint1 low 
affinity. Data are expressed as the mean ± SEM (n = 1 independent experiments, 2 
biological replicates). Statistical significance analyzed using a 2way ANOVA with 






Figure S10 Mint1 PTB domain binds PIP2, not clathrin 
A, GFP-Mint1 mutants or GFP-Mint2 WT were transfected into HEK293T cells and 
subject to immunoprecipitation with a GFP antibody. Representative immunoblots for 
GFP-Mint and clathrin from immunoprecipitation (IP, top two blots), total lysate (Input, 
third and fourth blot) and control Tubulin (bottom). (n = 4 independent experiments). B, 
HEK293T lysate infected with Dab1 or GFP-Mint1 PTB mutants was incubated with 
PIP2 beads (or control beads) for a pull down. Representative immunoblots for the GFP-
Mint1 PTB pulldown (top), positive control Dab1 pulldown (second blot), GFP-Mint1 
PTB and Dab1 input (third and fourth blots) and control Tubulin (bottom). (n= 1 
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